0001558370-21-009460 10-Q 60 20210630 20210728 20210728

Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231

10-Q 34 001-39202 211122435

1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913

1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312

QR Pharma, Inc. 20091202

10-Q 1 anvs-20210630x10q.htm 10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER 001-39202

Annovis Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware		26-2540421
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1055 Westlakes Drive, Suite 300

Berwyn, PA 19312

(Address of registrant’s principal executive offices)

(610) 727-3913

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		ANVS		NYSE American

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No.

The number of outstanding shares of the registrant’s common stock as of July 26, 2021 was: 8,100,570.

Table of Contents

ANNOVIS BIO, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED JUNE 30, 2021

PART I – FINANCIAL INFORMATION		Page


Item 1.	Financial Statements	3

	Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020	3

	Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited)	4

	Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited)	5

	Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (Unaudited)	6

	Notes to Financial Statements (Unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3.	Quantitative and Qualitative Disclosure About Market Risk	21

Item 4.	Controls and Procedures	21


PART II – OTHER INFORMATION


Item 1.	Legal Proceedings	22

Item 1A.	Risk Factors	22

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 3.	Defaults Upon Senior Securities	22

Item 4.	Mine Safety Disclosures	22

Item 5.	Other Information	22

Item 6.	Exhibits	23

	Signatures	24

Table of Contents

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

Annovis Bio, Inc.

Balance Sheets


	June 30,		December 31,
	2021		2020
		(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	49,224,198	$	8,074,658
Prepaid expenses and other current assets		272,040		44,676
Total current assets		49,496,238		8,119,334
Total assets	$	49,496,238	$	8,119,334
Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity
Current liabilities:
Accounts payable	$	114,828	$	341,856
Accrued expenses		769,247		236,524
Total current liabilities		884,075		578,380
Total liabilities		884,075		578,380
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized, and 0 shares issued and outstanding		—		—
Common stock - $0.0001 par value, 35,000,000 shares authorized, and 8,090,932 and 6,891,608 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively		809		689
Additional paid-in capital		68,574,704		21,779,340
Accumulated deficit		(19,963,350)		(14,239,075)
Total stockholders’ equity		48,612,163		7,540,954
Total liabilities and stockholders’ equity	$	49,496,238	$	8,119,334

See accompanying notes to financial statements.

Table of Contents

Annovis Bio, Inc.

Statements of Operations

(unaudited)


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Operating expenses:
Research and development	$	1,824,502	$	856,478	$	4,214,085	$	922,924
General and administrative		709,648		1,687,151		1,549,275		2,203,867
Total operating expenses		2,534,150		2,543,629		5,763,360		3,126,791
Operating loss		(2,534,150)		(2,543,629)		(5,763,360)		(3,126,791)
Other income (expense):
Change in fair value of derivative liability		—		—		—		(26,500)
Interest income (expense), net		2,134		25,878		2,331		36,512
Grant income		7,414		208,261		36,754		365,699
Total other income (expense)		9,548		234,139		39,085		375,711
Loss before income taxes		(2,524,602)		(2,309,490)		(5,724,275)		(2,751,080)
Income tax expense (benefit)		—		—		—		—
Net loss	$	(2,524,602)	$	(2,309,490)	$	(5,724,275)	$	(2,751,080)
Basic and diluted loss per common share	$	(0.34)	$	(0.34)	$	(0.80)	$	(0.48)
Weighted average number of common shares outstanding, basic and diluted		7,366,654		6,860,847		7,144,870		5,730,158

See accompanying notes to financial statements.

Table of Contents

Annovis Bio, Inc.

Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(unaudited)


	Redeemable Convertible Preferred Stock						Stockholders’ Equity (Deficit)
														Total
										Additional				Stockholders’
	Series A			Series A-1			Common Stock			Paid-In		Accumulated		Equity
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		(Deficit)
Three and Six Months Ended June 30, 2021
Balance, December 31, 2020	—	$	—	—	$	—	6,891,608	$	689	$	21,779,340	$	(14,239,075)	$	7,540,954
Exercise of stock options	—		—	—		—	3,868		1		3,016		—		3,017
Exercise of warrants	—		—	—		—	51,644		5		(5)		—		—
Share-based compensation expense	—		—	—		—	—		—		23,977		—		23,977
Net loss	—		—	—		—	—		—		—		(3,199,673)		(3,199,673)
Balance, March 31, 2021	—	$	—	—	$	—	6,947,120	$	695	$	21,806,328	$	(17,438,748)	$	4,368,275
Issuance of common stock, net of issuance costs	—		—	—		—	1,000,000		100		46,668,313		—		46,668,413
Exercise of stock options	—		—	—		—	141,532		14		92,071		—		92,085
Exercise of warrants	—		—	—		—	2,280		—		—		—		—
Share-based compensation expense	—		—	—		—	—		—		7,992		—		7,992
Net loss	—		—	—		—	—		—		—		(2,524,602)		(2,524,602)
Balance, June 30, 2021	—	$	—	—	$	—	8,090,932	$	809	$	68,574,704	$	(19,963,350)	$	48,612,163

Three and Six Months Ended June 30, 2020
Balance, December 31, 2019	5,133,159	$	6,509,303	630,722	$	567,649	282,614	$	28	$	200,600	$	(8,777,028)	$	(8,576,400)
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering	(5,133,159)		(6,509,303)	(630,722)		(567,649)	4,117,089		412		7,076,540		—		7,076,952
Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering	—		—	—		—	118,470		12		672,512		—		672,524
Issuance of common stock in initial public offering, net of issuance costs	—		—	—		—	2,300,000		230		11,955,565		—		11,955,795
Exercise of stock options	—		—	—		—	27,286		3		4,603		—		4,606
Net loss	—		—	—		—	—		—		—		(441,590)		(441,590)
Balance, March 31, 2020	—	$	—	—	$	—	6,845,459	$	685	$	19,909,820	$	(9,218,618)	$	10,691,887
Exercise of stock options	—		—	—		—	21,149		2		4,609		—		4,611
Share-based compensation expense	—		—	—		—	—		—		1,111,272		—		1,111,272
Net loss	—		—	—		—	—		—		—		(2,309,490)		(2,309,490)
Balance, June 30, 2020	—	$	—	—	$	—	6,866,608	$	687	$	21,025,701	$	(11,528,108)	$	9,498,280

See accompanying notes to financial statements.

Table of Contents

Annovis Bio, Inc.

Statements of Cash Flows

(unaudited)


	Six Months Ended June 30,
	2021		2020
Cash flows from operating activities:
Net loss	$	(5,724,275)	$	(2,751,080)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred financing fees		—		129
Amortization of debt discount		—		396
Share-based compensation expense, including stock issued to consultants and advisors		31,969		1,111,272
Change in fair value of derivative liability		—		26,500
Changes in operating assets and liabilities:
Grant receivable		—		535,854
Prepaid expenses and other current assets		(227,364)		(228,146)
Accounts payable		(232,028)		(913,071)
Accrued expenses		532,267		(64,065)
Net cash used in operating activities		(5,619,431)		(2,282,211)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs		46,673,869		12,034,406
Proceeds from exercise of stock options		95,102		9,217
Net cash provided by financing activities		46,768,971		12,043,623
Net increase in cash		41,149,540		9,761,412
Cash and cash equivalents, beginning of period		8,074,658		1,858
Cash and cash equivalents, end of period	$	49,224,198	$	9,763,270
Supplemental disclosure of non-cash financing activities:
Common stock issuance costs in accounts payable and accrued expenses	$	5,456	$	—
Conversion of redeemable convertible preferred stock to common stock	$	—	$	7,076,952
Conversion of convertible promissory notes, including embedded derivative, to common stock	$	—	$	672,524

See accompanying notes to financial statements.

Table of Contents

Annovis Bio, Inc.

Notes to Financial Statements

(Unaudited)

(1) Nature of Business and Liquidity

Annovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and Down syndrome patients with AD (“DS-AD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company’s lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.

Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.

The Company has a history of incurring net losses and had an accumulated deficit of $19,963,350 as of June 30, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of equity securities.

The Company closed its initial public offering (the “IPO”) on January 31, 2020, pursuant to which it sold a total of 2,300,000 shares of common stock at an initial offering price of $6.00 per share for total gross proceeds of approximately $13.8 million. The net proceeds of the IPO were approximately $12.0 million after deducting underwriting discounts and issuance costs paid by the Company. In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes converted into shares of Company common stock totaling 4,117,089 and 118,470, respectively. The Company’s common stock trades on the NYSE American under the ticker symbol “ANVS”.

On May 26, 2021, the Company closed an underwritten public offering of 1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0 million. The net proceeds of the offering were approximately $46.7 million, after deducting underwriting discounts and issuance costs paid or payable by the Company.

As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12 months, including the completion of its Phase 2a clinical trial in AD and PD (the “AD/PD Trial”) in the third quarter of 2021 and a potential Phase 3 trial in DS-AD. In order to fund additional planned Phase 3 trials in AD and PD, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.

Table of Contents

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at June 30, 2021, and its results of operations and its cash flows for the three and six months ended June 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.

(e) Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

Table of Contents

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.

(g) Research and Development

Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

(h) Grant Income

Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

(i) Share-Based Compensation

Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.

Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.

The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2021 and December 31, 2020, the Company has recorded a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income

Table of Contents

taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at June 30, 2021 or December 31, 2020.

(k) Recent Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company’s financial statements.

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020:


			Fair Value Measurement at
			June 30, 2021
	Carrying Value		Level 1		Level 2		Level 3
Cash and cash equivalents	$	49,224,198	$	49,224,198	$	—	$	—


			Fair Value Measurement at
			December 31, 2020
	Carrying Value		Level 1		Level 2		Level 3
Cash and cash equivalents	$	8,074,658	$	8,074,658	$	—	$	—

(4) Grant Receivable

In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of

Table of Contents

long-term chronic toxicology studies of ANVS401 in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $7,414 and $208,261 for the three months ended June 30, 2021 and 2020, respectively, and $36,754 and $365,699 for the six months ended June 30, 2021 and 2020, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 and $901,553 during the six months ended June 30, 2021 and 2020, respectively. The Company recorded a grant receivable of $0 as of June 30, 2021 and December 31, 2020, and had no unreimbursed, eligible costs incurred under the grant. As of June 30, 2021, there were no remaining funds available under the grant.

(5) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:


	June 30,		December 31,
	2021		2020
Prepaid insurance	$	213,892	$	26,542
Prepaid expenses		48,283		11,690
Security deposit		9,865		6,444
	$	272,040	$	44,676

(6) Accrued Expenses

Accrued expenses consisted of the following:


	June 30,		December 31,
	2021		2020
Payroll and related benefits	$	388,437	$	16,493
Accrued professional and clinical fees		353,977		216,198
Accrued license payments		26,833		3,833
	$	769,247	$	236,524

See Note 8 for further detail on the accrued license payments.

(7) Convertible Promissory Notes

In March 2019, the Company issued convertible promissory notes (the “Notes”) to various investors in the aggregate principal amount of $530,000 with a stated interest rate of 8% compounded annually. On issuance, the Company recognized a discount associated with the Notes related to the fair value of an embedded derivative liability reflecting the share-settlement feature providing for the conversion of the Notes at a 20% discount to the price of the shares issued in a qualified financing. The Company estimated the fair value of the derivative liability using a probability-weighted approach at issuance, as of the end of each reporting period and immediately prior to the closing of the IPO. The change in the fair value of the derivative liability was reflected in the statements of operations. The Company amortized deferred financing fees and debt discount over the term of the Notes as additional interest expense using the effective interest method. The effective interest rate on the Notes was 9.8%. The Company made no cash payments for interest on the Notes. On January 31, 2020, the Company closed its IPO and in accordance with the terms of the Notes, the outstanding Notes plus accrued interest converted into 118,470 shares of Company common stock.

Table of Contents

(8) Commitments and Contingencies

(a) Leases

The Company leases its office facilities under a month-to-month operating lease. Total rental expense was $12,575 and $10,336 for the three months ended June 30, 2021 and 2020, respectively and $23,190 and $20,815 for the six months ended June 30, 2021 and 2020, respectively.

(b) License Agreement

The Company licenses the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the “Licensor”). Under the license agreement, the Company pays a minimum annual commitment of $46,000 and is required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Company has paid to the Licensor all annual fees through November 2020. At June 30, 2021 and December 31, 2020, the Company had accrued $26,833 and $3,833, respectively, in license payments under the term of this license, included in accrued liabilities. No milestones have been achieved as of June 30, 2021. The Licensor also granted the Company a buy-out option which may be exercised at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company has the right to terminate the agreement at any time by giving 90 days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement are recognized in general and administrative expense in the statements of operations.

In July 2021, the Company gave notice to the Licensor of its termination of the license agreement.

The maximum aggregate severance payments under the Company’s employment agreements with its executive officers are approximately $930,000.

(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. At June 30, 2021 and December 31, 2020, the Company did not have any pending legal actions.

(e) Risks and Uncertainties

The extent to which the COVID-19 pandemic could have a material impact on the Company’s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

(9) Redeemable Convertible Preferred Stock and Stockholders’ Equity

(a) Overview

In connection with the closing of the Company’s IPO on January 31, 2020, the then-outstanding 5,133,159 shares of Series A and 630,722 shares of Series A-1 redeemable convertible preferred stock converted into an aggregate of 4,117,089 shares of Company common stock.

Table of Contents

The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020 to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a par value of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.

(b) Common Stock

1. Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.

2. Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

3. Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of June 30, 2021 or December 31, 2020.

(d) Warrants

In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which was 125% of the initial public offering price. The warrants have a five-year term and are exercisable commencing January 29, 2021. During the six months ended June 30, 2021, 97,600 of the warrants were tendered to the Company by the holders pursuant to cashless exercises. As of June 30, 2021 and December 31, 2020, 2,400 and 100,000 of the warrants were outstanding, respectively. The Company accounts for the warrants as a component of stockholders’ equity.

(10) Share-Based Compensation

Effective upon the closing of the Company’s IPO on January 31, 2020, the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective, succeeding the Company’s previous plan (see Note 1). As of the effective date of the 2019 Plan, the previous plan had 352,282 options outstanding 2019 Plan and no new awards may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 shares to 2,000,000. As of June 30, 2021, 1,168,664 shares were available for future grants.

There were no options or stock awards issued during the six months ended June 30, 2021. Share-based compensation expense for the three months ended June 30, 2021 and 2020 was $7,992 and $1,111,272, respectively, and for the six months ended June 30, 2021 and 2020 was $31,970 and $1,111,172, respectively. As of June 30, 2021, there were 961,653 options outstanding, all of which were vested and exercisable. As of December 31, 2020, there were 1,111,466 options outstanding, of which 1,061,466 were vested and exercisable.

Table of Contents

(11) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Numerator:
Net loss	$	(2,524,602)	$	(2,309,490)	$	(5,724,275)	$	(2,751,080)
Denominator:
Weighted-average common shares outstanding, basic and diluted		7,366,654		6,860,847		7,144,870		5,730,158

Net loss per share, basic and diluted	$	(0.34)	$	(0.34)	$	(0.80)	$	(0.48)

The Company reported a net loss for the three and six months ended June 30, 2021 and 2020, therefore, the basic and diluted net loss per share are the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows:


	June 30,
	2021	2020
Stock options	961,653	903,847
Warrants	2,400	100,000

In addition, common shares issuable upon the conversion of the Notes were excluded for all periods in which the Notes were outstanding.

(12) Income Taxes

The Company’s income tax benefit (expense) was $0.0 million for the three and six months ended June 30, 2021 and 2020. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss (“NOL”) that would have been recognized in the three and six months ended June 30, 2021 and 2020 was offset by changes in the valuation allowance.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.

Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.

As of June 30, 2021, and December 31, 2020, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.

Table of Contents

(13) Related-Party Transactions

As discussed in Note 7, in March 2019 the Company issued Notes in the aggregate principal amount of $530,000. Three of the Company’s directors purchased an aggregate of $305,000 of the Notes. On January 31, 2020, the Company closed its IPO, and the outstanding Notes plus accrued interest held by directors converted into 71,429 shares of Company common stock.

(14) Subsequent Events

On July 7, 2021, the Company granted options to purchase an aggregate of 84,200 shares of common stock at an exercise price of $102.85 per share to employees, members of the board of directors and consultants to the Company. Under the grant agreements, all of the options vest in substantially equal quarterly installments over two years and have a 10-year term.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

●

our business strategies;

●

the timing of regulatory submissions;

●

our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;

●

risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;

●

risks related to market acceptance of products;

●

risks associated with our reliance on third-party organizations;

●

our competitive position;

●

assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates;

●

our intellectual property position and our ability to maintain and protect our intellectual property rights;

●

our results of operations, financial condition, liquidity, prospects, and growth strategies;

●

our cash needs and financing plans;

●

the industry in which we operate; and

●

the trends that may affect the industry or us.

You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020 for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Those factors are updated, as applicable, in “Factors that May Affect Future Results” below. As a result of the risks, uncertainties and assumptions described above and elsewhere, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the

Table of Contents

significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with: (i) the interim financial statements and related notes thereto which are included in this Quarterly Report on Form 10-Q; and (ii) our annual financial statements for the year ended December 31, 2020 which are included in our Annual Report on Form 10-K for the year ended December 31, 2020.

Company Overview

We are a clinical stage, drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and Down Syndrome patients with AD (“DS-AD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. Our lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of neurotoxic proteins—amyloid precursor protein APP/Aβ (“APP”), tau/phospho-tau (“tau”) and α-Synuclein (“αSYN”)—thereby impeding the toxic cascade. Human studies in four mildly cognitive impaired patients have shown that ANVS401 lowered the levels of neurotoxic proteins and inflammatory factors. In preclinical studies, lower neurotoxic protein levels led to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.

We are presently conducting two Phase 2a clinical trials. In collaboration with the Alzheimer’s Disease Cooperative Study (“ADCS”) we are conducting a trial in 24 early AD patients (the “ADCS Trial”). Under an agreement with UC San Diego, where ADCS is located, we have contracted to provide study supplies at our cost but the remaining costs of the ADCS Trial are paid for by the National Institutes of Health (“NIH”). We are also conducting a Phase 2a clinical trial in 14 AD and 54 PD patients (the “AD/PD Trial”) which began treating patients in August 2020. Both clinical trials are double-blind, placebo-controlled studies.

The extent to which the COVID-19 pandemic could have a material impact on our current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. We continue to evaluate the potential impact.

We have never been profitable and have incurred net losses since inception. Our accumulated deficit at June 30, 2021 was $19,963.4 thousand. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.

Table of Contents

Results of Operations

Operating expenses and other income (expense) were comprised of the following:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

	(in thousands)				(in thousands)
Operating expenses:
Research and development	$	1,824.5	$	856.5	$	4,214.1	$	922.9
General and administrative		709.6		1,687.2		1,549.3		2,203.9
Other income (expense):
Change in fair value of derivative liability		—		—		—		(26.5)
Interest income (expense), net		2.1		25.9		2.3		36.5
Grant income		7.4		208.3		36.8		365.7

Three Months Ended June 30, 2021 and 2020

Research and Development Expenses

Research and development expenses increased by $968.0 thousand for the three months ended June 30, 2021 compared to the prior year period. The increase was primarily the result of an increase of $975.9 thousand in expenses related to our AD/PD Trial. For the year ending December 31, 2021, we expect research and development expenses to be higher than the prior year as we complete our AD/PD Trial and commence the planning of a Phase 3 study.

General and Administrative Expenses

General and administrative expenses decreased by $977.6 thousand for the three months ended June 30, 2021 compared to the prior year period. The decrease was primarily the result of a decrease in share-based compensation expense of $1,103.3 thousand, partially offset by an increase in recruiting expenses. We expect general and administrative expenses in 2021 will be higher as compared to 2020 due to increased personnel expenses.

Interest Income (Expense), Net

Interest income (expense), net decreased $23.8 thousand for the three months ended June 30, 2021 compared to the prior year period. The decrease was primarily the result of lower interest rates compared to the prior year period.

Grant Income

Grant income decreased $200.9 thousand for the three months ended June 30, 2021 compared to the prior year period. The income relates to a grant from the NIH to reimburse the costs of our long-term toxicology studies in rats and dogs, which was substantially completed in 2020.

Six Months Ended June 30, 2021 and 2020

Research and Development Expenses

Research and development expenses increased by $3,291.2 thousand for the six months ended June 30, 2021 compared to the prior year period. The increase was primarily the result of an increase of $2,918.1 thousand in expenses related to our AD/PD Trial and an increase of $276.6 thousand in personnel expenses. For the year ending December 31, 2021, we expect research and development expenses to be higher than the prior year as we complete our AD/PD Trial and commence the planning of a Phase 3 study.

Table of Contents

General and Administrative Expenses

General and administrative expenses decreased by $654.6 thousand for the six months ended June 30, 2021 compared to the prior year period. The decrease was primarily the result of a decrease in share-based compensation expense of $1,079.3 thousand, partially offset by an increase of $360.0 thousand in accrued incentive compensation expense and an increase in recruiting expenses. We expect general and administrative expenses in 2021 will be higher as compared to 2020 due to increased personnel expenses.

Change in Fair Value of Derivative Liability

The derivative liability represents an embedded derivative in our convertible promissory notes which were issued in March 2019. At each balance sheet date, we estimated the fair value of the derivative liability and recognized any change in our statements of operations. The fair value of the derivative liability was adjusted to $132.5 thousand immediately prior to the closing of the IPO on January 31, 2020. Effective upon the closing of the IPO, the derivative liability was eliminated, and the amount was reclassified to additional paid-in capital on the balance sheet.

Interest Income (Expense), Net

Interest income (expense), net decreased $34.2 thousand for the six months ended June 30, 2021 compared to the prior year period. The decrease was primarily the result of lower interest rates compared to the prior year period.

Grant Income

Grant income decreased $328.9 thousand for the six months ended June 30, 2021 compared to the prior year period. The income relates to a grant from the NIH to reimburse the costs of our long-term toxicology studies in rats and dogs, which was substantially completed in 2020.

Liquidity and Capital Resources

Since our inception in 2008, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of common stock, redeemable convertible preferred stock, and convertible promissory notes and funding from research grants. To date, we have not generated any revenues from the sale of products, and we do not anticipate generating any revenues from the sales of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of June 30, 2021, our principal source of liquidity was our cash, which totaled $49,224.2 thousand.

Equity Financings

We closed our IPO on January 31, 2020, raising gross proceeds of $13,800.0 thousand and net proceeds of $12,034.4 thousand, after deducting underwriting discounts and commissions and issuance costs paid by us, in the three months ended March 31, 2020.

We closed an equity offering on May 26, 2021, raising gross proceeds of $50,000.0 thousand and net proceeds of $46,668.4 thousand, after deducting underwriting discounts and commissions and issuance costs paid or payable by us, in the three months ended June 30, 2021.

Debt Financings

In March 2019 we issued $530.0 thousand principal amount of convertible promissory notes. Upon the closing of our IPO on January 31, 2020, the outstanding convertible promissory notes plus accrued interest converted into 118,470 shares of our common stock at a 20% discount to the public offering price.

Table of Contents

Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities.


	Six Months Ended
	June 30,
	2021		2020

	(in thousands)
Statement of Cash Flows Data:
Total net cash provided by (used in):
Operating activities	$	(5,619.4)	$	(2,282.2)
Financing activities		46,768.9		12,043.6
Increase in cash and cash equivalents	$	41,149.5	$	9,761.4

Operating Activities

For the six months ended June 30, 2021, cash used in operations increased $3,337.2 thousand compared to the same period in the prior year. The increase in cash used in operations was primarily the result of the ongoing costs of our AD/PD Trial.

We expect cash used in operating activities to increase in 2021 as compared to 2020 due to an expected increase in our operating losses associated with ongoing development of our product candidates, including our AD/PD Trial.

Financing Activities

Cash provided by financing activities was $46,768.9 thousand during the six months ended June 30, 2021, attributable to net proceeds from our equity offering of approximately $46,673.9 thousand and $95.1 thousand proceeds from the exercise of stock options.

Cash provided by financing activities was $12,043.6 thousand during the six months ended June 30, 2020, attributable to net proceeds from our IPO of $12,034.4 thousand, and $9.2 thousand proceeds from the exercise of stock options.

Funding Requirements

We expect that current cash and cash equivalents will be sufficient to fund our operations and capital requirements for at least the next 12 months. We believe that these available funds will be sufficient to complete our Phase 2a clinical trials for ANVS401 and to complete a Phase 3 study in DS-AD patients for this product candidate. However, it is difficult to predict our spending for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control.

To the extent that our capital resources are insufficient to meet our future operating and capital requirements, we will need to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.

Table of Contents

Contractual Obligations and Other Commitments

This item is not required for smaller reporting companies.

Factors that May Affect Future Results

You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020 for a discussion of important factors that may affect our future results.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined by applicable SEC regulations.

Discussion of Critical Accounting Policies and Significant Judgments and Estimates

The preparation of financial statements in conformity with GAAP requires us to use judgment in making certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in our financial statements and accompanying notes. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require difficult, subjective and complex judgments by management in order to make estimates about the effect of matters that are inherently uncertain. During the three months ended June 30, 2021, there were no significant changes to our critical accounting policies from those described in our annual financial statements for the year ended December 31, 2020, which we included in our Annual Report on Form 10-K for the year ended December 31, 2020.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

This item is not required for smaller reporting companies.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that the information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(f) and 15d-15(f) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.

Item 1A. Risk Factors

This item is not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits


Exhibit Number		Description of Exhibit

1.1		Underwriting Agreement, dated as of May 23, 2021, between Annovis Bio, Inc. and ThinkEqutiy, a division of Fordham Financial Management, Inc. (Incorporated by reference to Exhibit 1.1 to Form 8-K filed May 24, 2021.)

3.1		Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to Form 8-K filed February 6, 2020.)

3.2		Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit 3.2 to Form 8-K filed February 6, 2020.)

31.1		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


101.INS		XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Labels Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Signature	Title	Date

/s/ MARIA MACCECCHINI	President and Chief Executive Officer (principal	July 28, 2021
Maria Maccecchini	executive officer)

/s/ JEFFREY MCGROARTY	Chief Financial Officer (principal financial and	July 28, 2021
Jeffrey McGroarty	accounting officer)

EX-31.1 2 anvs-20210630xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Maria Maccecchini, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: July 28, 2021	/s/ Maria Maccecchini
	Maria Maccecchini
	President and Chief Executive Officer

EX-31.2 3 anvs-20210630xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey McGroarty, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: July 28, 2021	/s/ Jeffrey McGroarty
	Jeffrey McGroarty
	Chief Financial Officer

EX-32.1 4 anvs-20210630xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: July 28, 2021	/s/ Maria Maccecchini
	Maria Maccecchini
	President and Chief Executive Officer

EX-32.2 5 anvs-20210630xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey McGroarty, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: July 28, 2021	/s/ Jeffrey McGroarty
	Jeffrey McGroarty
	Chief Financial Officer

EX-101.SCH 6 anvs-20210630.xsd EX-101.SCH 00100 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business and Liquidity link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Grant Receivable link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Convertible Promissory Notes link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Grant Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Convertible Promissory Notes (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Commitments and Contingencies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Commitments and Contingencies - License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Commitments and Contingencies - Employment Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 anvs-20210630_cal.xml EX-101.CAL EX-101.DEF 8 anvs-20210630_def.xml EX-101.DEF EX-101.LAB 9 anvs-20210630_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Document Information [Line Items] Document and Entity Information Entity Registrant Name Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Balance Sheets Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents, Carrying Value Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits. Prepaid Expense, Security Deposits, and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Assets, Current Total current assets Assets Total assets Liabilities and Equity [Abstract] Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Accrued Liabilities and Interest, and Employee-Related Liabilities, Current Accrued expenses Total accrued expenses Liabilities, Current Total current liabilities Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 8) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock - $0.0001 par value, 2,000,000 shares authorized, and 0 shares issued and outstanding Common Stock, Value, Issued Common stock - $0.0001 par value, 35,000,000 shares authorized, and 6,947,120 and 6,891,608 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Number of preferred shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Number of common shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Statements of Operations Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Operating loss Nonoperating Income (Expense) [Abstract] Other income (expense): Unrealized Gain (Loss) on Derivatives Change in fair value of derivative liability Change in fair value of derivative liability Interest Income (Expense), Nonoperating, Net Interest income (expense), net Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606. Income from Grants Grant income Nonoperating Income (Expense) Total other income (expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Income tax expense (benefit) Net Income (Loss) Attributable to Parent Net loss Net loss Earnings Per Share, Basic and Diluted Net loss per share, basic and diluted Basic and diluted loss per common share Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average number of common shares outstanding, basic and diluted Weighted-average common shares outstanding, basic and diluted Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Redeemable Convertible Preferred Stock [Member] Redeemable convertible preferred stock Series A Redeemable convertible preferred stock. Seriesa Redeemable Convertible Preferred Stock [Member] Series A Redeemable convertible preferred stock Series A-1 Redeemable convertible preferred stock. Series1 Redeemable Convertible Preferred Stock [Member] Series A-1 Redeemable convertible preferred stock Increase (Decrease) in Temporary Equity [Roll Forward] Changes in Redeemable Convertible Preferred Stock Temporary Equity, Carrying Amount, Attributable to Parent Balance Balance Temporary Equity, Shares Issued Balance, shares Balance, shares Conversion of redeemable convertible preferred stock to common stock. Temporary Equity, Conversion of Preferred Stock to Common Stock Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering Conversion of redeemable convertible preferred stock to common stock, shares. Temporary Equity, Shares, Conversion of Preferred Stock to Common Stock Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares Conversion of redeemable convertible preferred stock to common stock, shares Increase (Decrease) in Stockholders' Equity [Roll Forward] Changes in Stockholders' Equity Shares, Issued Balance, shares Balance, shares The value of stock issued during the period upon the conversion of convertible preferred stock. Stock Issued During Period, Value, Conversion Of Convertible Securities, Preferred Stock Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering Number of shares issued during the period as a result of the conversion of convertible preferred stock. Stock Issued During Period, Shares, Conversion Of Convertible Securities, Preferred Stock Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares Number of shares issued for the conversion of redeemable convertible preferred stock The value of stock issued during the period upon the conversion of convertible promissory notes. Stock Issued During Period, Value, Conversion Of Convertible Securities, Convertible Promissory Notes Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering Number of shares issued during the period as a result of the conversion of convertible notes. Stock Issued During Period, Shares, Conversion of Convertible Notes Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering, shares Number of common shares issued upon conversion of notes Stock Issued During Period, Value, New Issues Issuance of common stock in initial public offering, net of issuance costs Stock Issued During Period, Shares, New Issues Issuance of common stock in initial public offering, net of issuance costs (in shares) Issuance of common stock Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options, shares Value of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Exercise of warrants Shares of stock issued as a result of the exercise of warrants. Stock Issued During Period, Shares, Warrants Exercised Exercise of warrants, shares Shares issued upon exercise of warrants APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Share based compensation expense Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Amortization of Debt Issuance Costs Amortization of deferred financing fees Amortization of Debt Discount (Premium) Amortization of debt discount Share-based Payment Arrangement, Noncash Expense Share-based compensation expense Share-based compensation expense, including stock issued to consultants and advisors Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: The increase (decrease) during the reporting period in grants receivable. Increase (Decrease) in Grants Receivable Grant receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of issuance costs Gross proceeds from issuance of common shares Proceeds from Stock Options Exercised Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of year Cash and cash equivalents, beginning of year Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of non-cash financing activities: The increase (decrease) during the reporting period in the deferred offering costs included in accounts payable and accrued liabilities. Increase (Decrease) Deferred Offering Costs Included in Accounts Payable and Accrued Liabilities Common stock issuance costs in accounts payable and accrued expenses The increase (decrease) during the reporting period in the conversion of redeemable convertible preferred stock to common stock. Conversion of Redeemable Convertible Preferred Stock to Common Stock Conversion of redeemable convertible preferred stock to common stock The increase (decrease) during the reporting period in the conversion of convertible promissory notes, including embedded derivative, to common stock Conversion of Convertible Promissory Notes, Including Embedded Derivative, to Common Stock Conversion of convertible promissory notes, including embedded derivative, to common stock Nature of Business and Liquidity Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Nature of Business and Liquidity Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements No definition available Grant Receivable The entire disclosure for grants receivables. Grants Receivable Disclosure [Text Block] Grant Receivable Prepaid Expenses and Other Current Assets The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block] Prepaid Expenses and Other Current Assets Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Convertible Promissory Notes. Debt Disclosure [Text Block] Convertible Promissory Notes Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Redeemable Convertible Preferred Stock and Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Redeemable Convertible Preferred Stock and Stockholders' Equity Share-Based Compensation Share-based Payment Arrangement [Text Block] Share-Based Compensation Net Loss Per Share Earnings Per Share [Text Block] Net Loss Per Share Income Taxes Income Tax Disclosure [Text Block] Income Taxes Related-Party Transactions Related Party Transactions Disclosure [Text Block] Related-Party Transactions Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting [Text Block] Basis of Presentation of Interim Unaudited Financial Statements Use of Estimates, Policy [Policy Text Block] Use of Estimates Earnings Per Share, Policy [Policy Text Block] Basic and Diluted Net Income (Loss) per Share Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Disclosure of accounting policy for issuance costs associated with equity issuances. Issuance Costs Associated with Equity Issuances [Policy Text Block] Issuance Costs Associated with Equity Issuances Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Research, Development, and Computer Software, Policy [Policy Text Block] Research and Development Disclosure of accounting policy for grant income. Grant Income [Policy Text Block] Grant Income Share-based Payment Arrangement [Policy Text Block] Share-Based Compensation Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of prepaid expenses and other current assets Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of shares excluded from the computation of diluted weighted-average shares outstanding Schedule of Stock by Class [Table] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] First sale of stock by a private company to the public and right given to the underwriter to sell additional shares over the initial allotment. Initial Public Offering And Over Allotment Option [Member] IPO and Over-Allotment Option I P O [Member] IPO Secondary sale of stock. Secondary Public Offering [Member] Secondary Public Offering Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Represents information pertaining to Underwriters warrants. Underwriters Warrants [Member] Underwriters warrants Class of Stock [Line Items] Redeemable Convertible Preferred Stock and Stockholders' Equity No definition available. Nature of Business and Liquidity [Abstract] Nature of Business and Liquidity Revenue from Contract with Customer, Excluding Assessed Tax Revenue Share Price Share price Sale of Stock, Consideration Received on Transaction Net proceeds from issuance of common shares EX-101.PRE 10 anvs-20210630_pre.xml EX-101.PRE XML 11 anvs-20210630x10q_htm.xml IDEA: XBRL DOCUMENT 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2020-03-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2020-03-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2019-12-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2019-12-31 0001477845 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001477845 us-gaap:RetainedEarningsMember 2021-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001477845 us-gaap:RetainedEarningsMember 2021-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001477845 2021-03-31 0001477845 us-gaap:RetainedEarningsMember 2020-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001477845 us-gaap:RetainedEarningsMember 2020-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001477845 us-gaap:RetainedEarningsMember 2020-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001477845 2020-03-31 0001477845 us-gaap:RetainedEarningsMember 2019-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001477845 us-gaap:CommonStockMember 2021-06-30 0001477845 us-gaap:CommonStockMember 2021-03-31 0001477845 us-gaap:CommonStockMember 2020-12-31 0001477845 us-gaap:CommonStockMember 2020-06-30 0001477845 us-gaap:CommonStockMember 2020-03-31 0001477845 us-gaap:CommonStockMember 2019-12-31 0001477845 us-gaap:CommonStockMember anvs:SecondaryPublicOfferingMember 2021-05-26 0001477845 us-gaap:CommonStockMember anvs:InitialPublicOfferingAndOverAllotmentOptionMember 2020-01-31 0001477845 anvs:PreviousPlansMember 2020-01-31 0001477845 anvs:EquityIncentivePlan2019Member 2021-06-01 0001477845 anvs:EquityIncentivePlan2019Member 2021-05-31 0001477845 us-gaap:SubsequentEventMember 2021-07-07 2021-07-07 0001477845 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001477845 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001477845 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001477845 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001477845 us-gaap:CommonStockMember anvs:SecondaryPublicOfferingMember 2021-05-26 2021-05-26 0001477845 us-gaap:CommonStockMember anvs:InitialPublicOfferingAndOverAllotmentOptionMember 2020-01-31 2020-01-31 0001477845 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001477845 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001477845 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001477845 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001477845 us-gaap:ConvertibleDebtMember 2021-01-01 2021-06-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2021-06-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2020-12-31 0001477845 us-gaap:ConvertibleDebtMember anvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember srt:DirectorMember 2019-03-31 0001477845 us-gaap:ConvertibleDebtMember 2019-03-31 0001477845 anvs:UnderwritersWarrantsMember 2021-06-30 0001477845 anvs:UnderwritersWarrantsMember 2020-12-31 0001477845 2020-06-30 0001477845 2019-12-31 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001477845 us-gaap:WarrantMember 2021-01-01 2021-06-30 0001477845 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001477845 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001477845 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001477845 2021-01-01 2021-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001477845 2021-07-26 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2020-01-31 2020-01-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2020-01-31 2020-01-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001477845 2020-01-01 2020-03-31 0001477845 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001477845 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001477845 us-gaap:ConvertibleDebtMember anvs:RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember srt:DirectorMember us-gaap:CommonStockMember 2020-01-31 2020-01-31 0001477845 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-31 2020-01-31 0001477845 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001477845 us-gaap:ConvertibleDebtMember anvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember 2019-03-01 2019-03-31 0001477845 anvs:UnderwritersWarrantsMember 2020-01-31 0001477845 srt:ExecutiveOfficerMember 2021-06-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2021-01-01 2021-06-30 0001477845 anvs:HorizonTherapeuticsPlcMember us-gaap:LicenseAgreementTermsMember 2008-11-01 2008-11-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2021-04-01 2021-06-30 0001477845 2021-04-01 2021-06-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2021-01-01 2021-06-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2020-04-01 2020-06-30 0001477845 2020-04-01 2020-06-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2020-01-01 2020-06-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2019-09-30 0001477845 2021-01-01 2021-06-30 0001477845 anvs:UnderwritersWarrantsMember 2021-01-01 2021-06-30 0001477845 us-gaap:ConvertibleDebtMember 2019-03-01 2019-03-31 0001477845 2020-01-01 2020-06-30 0001477845 2020-01-31 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2021-06-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2020-12-31 0001477845 2021-06-30 0001477845 2020-12-31 iso4217:USD shares pure anvs:item anvs:Vote iso4217:USD shares

NYSE Non-accelerated Filer

0.0001

8090932

0001477845 --12-31 2021 Q2 false

6891608

10-Q true 2021-06-30 false 001-39202 Annovis Bio, Inc. DE 26-2540421 1055 Westlakes Drive, Suite 300 Berwyn PA 19312 610 727-3913 Common Stock, par value $0.0001 per share ANVS Yes Yes true true true false 8100570

49224198

8074658

272040 44676

49496238

8119334

49496238

8119334

114828

341856

769247 236524

884075

578380

884075

578380

0.0001

2000000

0.0001

35000000

8090932

6891608

809

689

68574704

21779340

-19963350

-14239075

48612163

7540954

49496238

8119334

1824502

856478

4214085

922924

709648

1687151

1549275

2203867

2534150

2543629

5763360

3126791

-2534150

-2543629

-5763360

-3126791

-26500

2134

25878

2331

36512

7414 208261 36754 365699

9548

234139

39085

375711

-2524602

-2309490

-5724275

-2751080

-2524602

-2309490

-5724275

-2751080

-0.34

-0.80

-0.48

7366654

6860847

7144870

5730158

6891608

689

21779340

-14239075

7540954

3868

3016

3017

51644 5 -5

23977

-3199673

6947120

695

21806328

-17438748

4368275

1000000

100

46668313

46668413

141532

92071

92085

2280

7992

-2524602

8090932

809

68574704

-19963350

48612163

5133159

6509303

630722

567649

282614

200600

-8777028

-8576400

5133159 6509303 630722 567649 4117089 412 7076540 7076952 118470 12 672512 672524

2300000

230

11955565

11955795

27286

4603

4606

-441590

6845459

685

19909820

-9218618

10691887

21149

4609

4611

1111272

-2309490

6866608

687

21025701

-11528108

9498280

-5724275

-2751080

129

396

31969

1111272

-26500

-535854

227364

228146

-232028

-913071

532267

-64065

-5619431

-2282211

46673869

12034406

95102

9217

46768971

12043623

41149540

9761412

8074658

1858

49224198

9763270

5456 7076952 672524

(1) Nature of Business and LiquidityAnnovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and Down syndrome patients with AD (“DS-AD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company’s lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.The Company has a history of incurring net losses and had an accumulated deficit of $19,963,350 as of June 30, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of equity securities.The Company closed its initial public offering (the “IPO”) on January 31, 2020, pursuant to which it sold a total of 2,300,000 shares of common stock at an initial offering price of $6.00 per share for total gross proceeds of approximately $13.8 million. The net proceeds of the IPO were approximately $12.0 million after deducting underwriting discounts and issuance costs paid by the Company. In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes converted into shares of Company common stock totaling 4,117,089 and 118,470, respectively. The Company’s common stock trades on the NYSE American under the ticker symbol “ANVS”. On May 26, 2021, the Company closed an underwritten public offering of 1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0 million. The net proceeds of the offering were approximately $46.7 million, after deducting underwriting discounts and issuance costs paid or payable by the Company.As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12 months, including the completion of its Phase 2a clinical trial in AD and PD (the “AD/PD Trial”) in the third quarter of 2021 and a potential Phase 3 trial in DS-AD. In order to fund additional planned Phase 3 trials in AD and PD, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.

-19963350

2300000

6.00

13800000

12000000.0

100000

7.50

1.25 4117089 118470

1000000

50.00

50000000.0

46700000

(2) Summary of Significant Accounting Policies(a) Basis of Presentation of Interim Unaudited Financial StatementsThe interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at June 30, 2021, and its results of operations and its cash flows for the three and six months ended June 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.(b) Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.(c) Basic and Diluted Net Income (Loss) per ShareBasic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.(d) Cash and Cash EquivalentsThe Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. (e) Issuance Costs Associated with Equity IssuancesIssuance costs incurred in connection with the Company’s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. (f) Fair Value of Financial InstrumentsThe Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature. (g) Research and DevelopmentResearch and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.(h) Grant IncomeGrants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.(i) Share-Based CompensationShare-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.(j) Income TaxesThe Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2021 and December 31, 2020, the Company has recorded a full valuation allowance against its deferred tax assets.The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at June 30, 2021 or December 31, 2020.(k) Recent Accounting PronouncementsIn December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company’s financial statements.

(a) Basis of Presentation of Interim Unaudited Financial StatementsThe interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at June 30, 2021, and its results of operations and its cash flows for the three and six months ended June 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

(c) Basic and Diluted Net Income (Loss) per ShareBasic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

(d) Cash and Cash EquivalentsThe Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.

(e) Issuance Costs Associated with Equity IssuancesIssuance costs incurred in connection with the Company’s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

(f) Fair Value of Financial InstrumentsThe Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.

(g) Research and DevelopmentResearch and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

(h) Grant IncomeGrants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

(i) Share-Based CompensationShare-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(j) Income TaxesThe Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2021 and December 31, 2020, the Company has recorded a full valuation allowance against its deferred tax assets.The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at June 30, 2021 or December 31, 2020.

(k) Recent Accounting PronouncementsIn December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company’s financial statements.

(3) Fair Value MeasurementsThe Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.29%;margin:0pt;padding:0pt;">Fair Value Measurement at </td></tr><tr><td style="vertical-align:bottom;width:51.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, 2021</td></tr><tr><td style="vertical-align:bottom;width:51.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Carrying Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.69%;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> 49,224,198</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> 49,224,198</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"> —</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.25%;margin:0pt;padding:0pt;">Fair Value Measurement at </td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2020</td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Carrying Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 8,074,658</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"> 8,074,658</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"></td></tr></table>

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.29%;margin:0pt;padding:0pt;">Fair Value Measurement at </td></tr><tr><td style="vertical-align:bottom;width:51.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, 2021</td></tr><tr><td style="vertical-align:bottom;width:51.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Carrying Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.69%;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> 49,224,198</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> 49,224,198</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"> —</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.25%;margin:0pt;padding:0pt;">Fair Value Measurement at </td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2020</td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Carrying Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 8,074,658</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"> 8,074,658</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"></td></tr></table>

49224198

8074658

(4) Grant ReceivableIn September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of ANVS401 in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $7,414 and $208,261 for the three months ended June 30, 2021 and 2020, respectively, and $36,754 and $365,699 for the six months ended June 30, 2021 and 2020, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 and $901,553 during the six months ended June 30, 2021 and 2020, respectively. The Company recorded a grant receivable of $0 as of June 30, 2021 and December 31, 2020, and had no unreimbursed, eligible costs incurred under the grant. As of June 30, 2021, there were no remaining funds available under the grant. 1900000 7414 208261 36754 365699 36754 901553

(5) Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Prepaid insurance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> 213,892</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> 26,542</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Prepaid expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> 48,283</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> 11,690</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Security deposit</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,865</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,444</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 272,040</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 44,676</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr></table>

213892

26542

48283

11690

9865

6444

272040 44676

(6) Accrued ExpensesAccrued expenses consisted of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Payroll and related benefits</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> 388,437</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> 16,493</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Accrued professional and clinical fees</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> 353,977</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> 216,198</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Accrued license payments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 26,833</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,833</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 769,247</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 236,524</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td></tr></table>See Note 8 for further detail on the accrued license payments.

388437

16493

353977

216198

26833 3833 769247 236524

(7) Convertible Promissory NotesIn March 2019, the Company issued convertible promissory notes (the “Notes”) to various investors in the aggregate principal amount of $530,000 with a stated interest rate of 8% compounded annually. On issuance, the Company recognized a discount associated with the Notes related to the fair value of an embedded derivative liability reflecting the share-settlement feature providing for the conversion of the Notes at a 20% discount to the price of the shares issued in a qualified financing. The Company estimated the fair value of the derivative liability using a probability-weighted approach at issuance, as of the end of each reporting period and immediately prior to the closing of the IPO. The change in the fair value of the derivative liability was reflected in the statements of operations. The Company amortized deferred financing fees and debt discount over the term of the Notes as additional interest expense using the effective interest method. The effective interest rate on the Notes was 9.8%. The Company made no cash payments for interest on the Notes. On January 31, 2020, the Company closed its IPO and in accordance with the terms of the Notes, the outstanding Notes plus accrued interest converted into 118,470 shares of Company common stock.

530000

0.08

0.20

0.098

118470

(8) Commitments and Contingencies(a) LeasesThe Company leases its office facilities under a month-to-month operating lease. Total rental expense was $12,575 and $10,336 for the three months ended June 30, 2021 and 2020, respectively and $23,190 and $20,815 for the six months ended June 30, 2021 and 2020, respectively.(b) License AgreementThe Company licenses the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the “Licensor”). Under the license agreement, the Company pays a minimum annual commitment of $46,000 and is required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Company has paid to the Licensor all annual fees through November 2020. At June 30, 2021 and December 31, 2020, the Company had accrued $26,833 and $3,833, respectively, in license payments under the term of this license, included in accrued liabilities. No milestones have been achieved as of June 30, 2021. The Licensor also granted the Company a buy-out option which may be exercised at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company has the right to terminate the agreement at any time by giving 90 days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement are recognized in general and administrative expense in the statements of operations. In July 2021, the Company gave notice to the Licensor of its termination of the license agreement.(c) Employment AgreementsThe maximum aggregate severance payments under the Company’s employment agreements with its executive officers are approximately $930,000.(d) LitigationThe Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. At June 30, 2021 and December 31, 2020, the Company did not have any pending legal actions.(e) Risks and UncertaintiesThe extent to which the COVID-19 pandemic could have a material impact on the Company’s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

12575

10336

23190

20815

46000 26833 3833 0 P90D 930000

(9) Redeemable Convertible Preferred Stock and Stockholders’ Equity(a) OverviewIn connection with the closing of the Company’s IPO on January 31, 2020, the then-outstanding 5,133,159 shares of Series A and 630,722 shares of Series A-1 redeemable convertible preferred stock converted into an aggregate of 4,117,089 shares of Company common stock. The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020 to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a par value of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.(b) Common Stock1. DividendsSubject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.2. LiquidationSubject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.3. VotingThe holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.(c) Preferred StockPreferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of June 30, 2021 or December 31, 2020.(d) WarrantsIn conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which was 125% of the initial public offering price. The warrants have a five-year term and are exercisable commencing January 29, 2021. During the six months ended June 30, 2021, 97,600 of the warrants were tendered to the Company by the holders pursuant to cashless exercises. As of June 30, 2021 and December 31, 2020, 2,400 and 100,000 of the warrants were outstanding, respectively. The Company accounts for the warrants as a component of stockholders’ equity.

5133159 630722 4117089 2 37000000

0.0001

35000000

2000000

100000

7.50

1.25

P5Y

97600

2400

100000

(10) Share-Based CompensationEffective upon the closing of the Company’s IPO on January 31, 2020, the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective, succeeding the Company’s previous plan (see Note 1). As of the effective date of the 2019 Plan, the previous plan had 352,282 options outstanding 2019 Plan and no new awards may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 shares to 2,000,000. As of June 30, 2021, 1,168,664 shares were available for future grants.There were no options or stock awards issued during the six months ended June 30, 2021. Share-based compensation expense for the three months ended June 30, 2021 and 2020 was $7,992 and $1,111,272, respectively, and for the six months ended June 30, 2021 and 2020 was $31,970 and $1,111,172, respectively. As of June 30, 2021, there were 961,653 options outstanding, all of which were vested and exercisable. As of December 31, 2020, there were 1,111,466 options outstanding, of which 1,061,466 were vested and exercisable.

352282

1000000

2000000

1168664

7992

1111272

31970

1111172

961653

1111466

1061466

(11) Net Loss Per ShareThe following table sets forth the computation of basic and diluted net loss per share:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;">Numerator:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;">Net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,524,602)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,309,490)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (5,724,275)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,751,080)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;">Denominator:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;">Weighted-average common shares outstanding, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 7,366,654</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 6,860,847</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 7,144,870</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 5,730,158</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;">Net loss per share, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.34)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.34)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.80)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.48)</td></tr></table>The Company reported a net loss for the three and six months ended June 30, 2021 and 2020, therefore, the basic and diluted net loss per share are the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:77.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:77.11%;margin:0pt;padding:0pt;">Stock options</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> 961,653</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> 903,847</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.11%;margin:0pt;padding:0pt;">Warrants</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> 2,400</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> 100,000</td></tr></table>In addition, common shares issuable upon the conversion of the Notes were excluded for all periods in which the Notes were outstanding.

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;">Numerator:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;">Net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,524,602)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,309,490)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (5,724,275)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,751,080)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;">Denominator:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;">Weighted-average common shares outstanding, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 7,366,654</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 6,860,847</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 7,144,870</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 5,730,158</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;">Net loss per share, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.34)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.34)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.80)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.48)</td></tr></table>

-2524602

-2309490

-5724275

-2751080

7366654

6860847

7144870

5730158

-0.34

-0.80

-0.48

961653

903847

2400

100000

(12) Income TaxesThe Company’s income tax benefit (expense) was $0.0 million for the three and six months ended June 30, 2021 and 2020. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss (“NOL”) that would have been recognized in the three and six months ended June 30, 2021 and 2020 was offset by changes in the valuation allowance.On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.As of June 30, 2021, and December 31, 2020, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.

0.0

(13) Related-Party TransactionsAs discussed in Note 7, in March 2019 the Company issued Notes in the aggregate principal amount of $530,000. Three of the Company’s directors purchased an aggregate of $305,000 of the Notes. On January 31, 2020, the Company closed its IPO, and the outstanding Notes plus accrued interest held by directors converted into 71,429 shares of Company common stock.

530000

305000

71429

(14) Subsequent EventsOn July 7, 2021, the Company granted options to purchase an aggregate of 84,200 shares of common stock at an exercise price of $102.85 per share to employees, members of the board of directors and consultants to the Company. Under the grant agreements, all of the options vest in substantially equal quarterly installments over two years and have a 10-year term.

84200

102.85

P2Y

P10Y

XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2021	Jul. 26, 2021
Document and Entity Information
Entity Registrant Name	Annovis Bio, Inc.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-39202
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-2540421
Entity Address, Address Line One	1055 Westlakes Drive, Suite 300
Entity Address, City or Town	Berwyn
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19312
City Area Code	610
Local Phone Number	727-3913
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ANVS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,100,570
Entity Central Index Key	0001477845
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 49,224,198	$ 8,074,658
Prepaid expenses and other current assets	272,040	44,676
Total current assets	49,496,238	8,119,334
Total assets	49,496,238	8,119,334
Current liabilities:
Accounts payable	114,828	341,856
Accrued expenses	769,247	236,524
Total current liabilities	884,075	578,380
Total liabilities	884,075	578,380
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized, and 0 shares issued and outstanding
Common stock - $0.0001 par value, 35,000,000 shares authorized, and 6,947,120 and 6,891,608 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	809	689
Additional paid-in capital	68,574,704	21,779,340
Accumulated deficit	(19,963,350)	(14,239,075)
Total stockholders' equity	48,612,163	7,540,954
Total liabilities and stockholders' equity	$ 49,496,238	$ 8,119,334

XML 14 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Balance Sheets
Preferred stock, par value (dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	35,000,000	35,000,000
Common stock, shares issued	8,090,932	6,891,608
Common stock, shares outstanding	8,090,932	6,891,608

XML 15 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Statements of Operations - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses:
Research and development	$ 1,824,502	$ 856,478	$ 4,214,085	$ 922,924
General and administrative	709,648	1,687,151	1,549,275	2,203,867
Total operating expenses	2,534,150	2,543,629	5,763,360	3,126,791
Operating loss	(2,534,150)	(2,543,629)	(5,763,360)	(3,126,791)
Other income (expense):
Change in fair value of derivative liability				(26,500)
Interest income (expense), net	2,134	25,878	2,331	36,512
Grant income	7,414	208,261	36,754	365,699
Total other income (expense)	9,548	234,139	39,085	375,711
Loss before income taxes	(2,524,602)	(2,309,490)	(5,724,275)	(2,751,080)
Income tax expense (benefit)			0.0	0.0
Net loss	$ (2,524,602)	$ (2,309,490)	$ (5,724,275)	$ (2,751,080)
Basic and diluted loss per common share	$ (0.34)	$ (0.34)	$ (0.80)	$ (0.48)
Weighted average number of common shares outstanding, basic and diluted	7,366,654	6,860,847	7,144,870	5,730,158

XML 16 R5.htm IDEA: XBRL DOCUMENT

Statements of Changes in Redeemable Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2020 USD ($) shares
Series A Redeemable convertible preferred stock
Changes in Redeemable Convertible Preferred Stock
Balance \| $	$ 6,509,303
Balance, shares \| shares	5,133,159
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering \| $	$ (6,509,303)
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares \| shares	(5,133,159)
Balance \| $	$ 0
Balance, shares \| shares	0
Series A-1 Redeemable convertible preferred stock
Changes in Redeemable Convertible Preferred Stock
Balance \| $	$ 567,649
Balance, shares \| shares	630,722
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering \| $	$ (567,649)
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares \| shares	(630,722)
Balance \| $	$ 0
Balance, shares \| shares	0

XML 17 R6.htm IDEA: XBRL DOCUMENT

Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 28	$ 200,600	$ (8,777,028)	$ (8,576,400)
Balance, shares at Dec. 31, 2019	282,614
Changes in Stockholders' Equity
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering	$ 412	7,076,540		7,076,952
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares	4,117,089
Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering	$ 12	672,512		672,524
Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering, shares	118,470
Issuance of common stock in initial public offering, net of issuance costs	$ 230	11,955,565		11,955,795
Issuance of common stock in initial public offering, net of issuance costs (in shares)	2,300,000
Exercise of stock options	$ 3	4,603		4,606
Exercise of stock options, shares	27,286
Net loss			(441,590)	(441,590)
Balance at Mar. 31, 2020	$ 685	19,909,820	(9,218,618)	10,691,887
Balance, shares at Mar. 31, 2020	6,845,459
Balance at Dec. 31, 2019	$ 28	200,600	(8,777,028)	(8,576,400)
Balance, shares at Dec. 31, 2019	282,614
Changes in Stockholders' Equity
Net loss				(2,751,080)
Balance at Jun. 30, 2020	$ 687	21,025,701	(11,528,108)	9,498,280
Balance, shares at Jun. 30, 2020	6,866,608
Balance at Mar. 31, 2020	$ 685	19,909,820	(9,218,618)	10,691,887
Balance, shares at Mar. 31, 2020	6,845,459
Changes in Stockholders' Equity
Exercise of stock options	$ 2	4,609		4,611
Exercise of stock options, shares	21,149
Share based compensation expense		1,111,272		1,111,272
Net loss			(2,309,490)	(2,309,490)
Balance at Jun. 30, 2020	$ 687	21,025,701	(11,528,108)	9,498,280
Balance, shares at Jun. 30, 2020	6,866,608
Balance at Dec. 31, 2020	$ 689	21,779,340	(14,239,075)	7,540,954
Balance, shares at Dec. 31, 2020	6,891,608
Changes in Stockholders' Equity
Exercise of stock options	$ 1	3,016		3,017
Exercise of stock options, shares	3,868
Exercise of warrants	$ 5	(5)
Exercise of warrants, shares	51,644
Share based compensation expense		23,977		23,977
Net loss			(3,199,673)	(3,199,673)
Balance at Mar. 31, 2021	$ 695	21,806,328	(17,438,748)	4,368,275
Balance, shares at Mar. 31, 2021	6,947,120
Balance at Dec. 31, 2020	$ 689	21,779,340	(14,239,075)	7,540,954
Balance, shares at Dec. 31, 2020	6,891,608
Changes in Stockholders' Equity
Net loss				(5,724,275)
Balance at Jun. 30, 2021	$ 809	68,574,704	(19,963,350)	48,612,163
Balance, shares at Jun. 30, 2021	8,090,932
Balance at Mar. 31, 2021	$ 695	21,806,328	(17,438,748)	4,368,275
Balance, shares at Mar. 31, 2021	6,947,120
Changes in Stockholders' Equity
Issuance of common stock in initial public offering, net of issuance costs	$ 100	46,668,313		46,668,413
Issuance of common stock in initial public offering, net of issuance costs (in shares)	1,000,000
Exercise of stock options	$ 14	92,071		92,085
Exercise of stock options, shares	141,532
Exercise of warrants, shares	2,280
Share based compensation expense		7,992		7,992
Net loss			(2,524,602)	(2,524,602)
Balance at Jun. 30, 2021	$ 809	$ 68,574,704	$ (19,963,350)	$ 48,612,163
Balance, shares at Jun. 30, 2021	8,090,932

XML 18 R7.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows - USD ($)	6 Months Ended
Statements of Cash Flows - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (5,724,275)	$ (2,751,080)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred financing fees		129
Amortization of debt discount		396
Share-based compensation expense, including stock issued to consultants and advisors	31,969	1,111,272
Change in fair value of derivative liability		26,500
Changes in operating assets and liabilities:
Grant receivable		535,854
Prepaid expenses and other current assets	(227,364)	(228,146)
Accounts payable	(232,028)	(913,071)
Accrued expenses	532,267	(64,065)
Net cash used in operating activities	(5,619,431)	(2,282,211)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	46,673,869	12,034,406
Proceeds from exercise of stock options	95,102	9,217
Net cash provided by financing activities	46,768,971	12,043,623
Net increase in cash	41,149,540	9,761,412
Cash and cash equivalents, beginning of year	8,074,658	1,858
Cash and cash equivalents, end of year	49,224,198	9,763,270
Supplemental disclosure of non-cash financing activities:
Common stock issuance costs in accounts payable and accrued expenses	$ 5,456
Conversion of redeemable convertible preferred stock to common stock		7,076,952
Conversion of convertible promissory notes, including embedded derivative, to common stock		$ 672,524

XML 19 R8.htm IDEA: XBRL DOCUMENT

Nature of Business and Liquidity

6 Months Ended

Jun. 30, 2021

Nature of Business and Liquidity

Nature of Business and Liquidity

(1) Nature of Business and Liquidity

XML 20 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2021

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

(b) Use of Estimates

(d) Cash and Cash Equivalents

(e) Issuance Costs Associated with Equity Issuances

(f) Fair Value of Financial Instruments

(g) Research and Development

(h) Grant Income

(i) Share-Based Compensation

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(j) Income Taxes

(k) Recent Accounting Pronouncements

XML 21 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2021

Fair Value Measurements

Fair Value Measurements

(3) Fair Value Measurements

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.


			Fair Value Measurement at
			June 30, 2021
	Carrying Value		Level 1		Level 2		Level 3
Cash and cash equivalents	$	49,224,198	$	49,224,198	$	—	$	—


			Fair Value Measurement at
			December 31, 2020
	Carrying Value		Level 1		Level 2		Level 3
Cash and cash equivalents	$	8,074,658	$	8,074,658	$	—	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Grant Receivable

6 Months Ended

Jun. 30, 2021

Grant Receivable

Grant Receivable

(4) Grant Receivable

XML 23 R12.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

6 Months Ended

Jun. 30, 2021

Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

(5) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:


	June 30,		December 31,
	2021		2020
Prepaid insurance	$	213,892	$	26,542
Prepaid expenses		48,283		11,690
Security deposit		9,865		6,444
	$	272,040	$	44,676

XML 24 R13.htm IDEA: XBRL DOCUMENT

Accrued Expenses

6 Months Ended

Jun. 30, 2021

Accrued Expenses

Accrued Expenses

(6) Accrued Expenses

Accrued expenses consisted of the following:


	June 30,		December 31,
	2021		2020
Payroll and related benefits	$	388,437	$	16,493
Accrued professional and clinical fees		353,977		216,198
Accrued license payments		26,833		3,833
	$	769,247	$	236,524

See Note 8 for further detail on the accrued license payments.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Convertible Promissory Notes

6 Months Ended

Jun. 30, 2021

Convertible Promissory Notes.

Convertible Promissory Notes

(7) Convertible Promissory Notes

XML 26 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2021

Commitments and Contingencies

Commitments and Contingencies

(8) Commitments and Contingencies

(a) Leases

(b) License Agreement

In July 2021, the Company gave notice to the Licensor of its termination of the license agreement.

The maximum aggregate severance payments under the Company’s employment agreements with its executive officers are approximately $930,000.

(d) Litigation

(e) Risks and Uncertainties

XML 27 R16.htm IDEA: XBRL DOCUMENT

Redeemable Convertible Preferred Stock and Stockholders' Equity

6 Months Ended

Jun. 30, 2021

Redeemable Convertible Preferred Stock and Stockholders' Equity

Redeemable Convertible Preferred Stock and Stockholders' Equity

(9) Redeemable Convertible Preferred Stock and Stockholders’ Equity

(a) Overview

(b) Common Stock

1. Dividends

2. Liquidation

3. Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of June 30, 2021 or December 31, 2020.

(d) Warrants

XML 28 R17.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

6 Months Ended

Jun. 30, 2021

Share-Based Compensation

Share-Based Compensation

(10) Share-Based Compensation

XML 29 R18.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

6 Months Ended

Jun. 30, 2021

Net Loss Per Share

Net Loss Per Share

(11) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Numerator:
Net loss	$	(2,524,602)	$	(2,309,490)	$	(5,724,275)	$	(2,751,080)
Denominator:
Weighted-average common shares outstanding, basic and diluted		7,366,654		6,860,847		7,144,870		5,730,158

Net loss per share, basic and diluted	$	(0.34)	$	(0.34)	$	(0.80)	$	(0.48)


	June 30,
	2021	2020
Stock options	961,653	903,847
Warrants	2,400	100,000

In addition, common shares issuable upon the conversion of the Notes were excluded for all periods in which the Notes were outstanding.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2021

Income Taxes

Income Taxes

(12) Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Related-Party Transactions

6 Months Ended

Jun. 30, 2021

Related-Party Transactions

Related-Party Transactions

(13) Related-Party Transactions

XML 32 R21.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2021

Subsequent Events

Subsequent Events

(14) Subsequent Events

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2021
Summary of Significant Accounting Policies
Basis of Presentation of Interim Unaudited Financial Statements	(a) Basis of Presentation of Interim Unaudited Financial Statements The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at June 30, 2021, and its results of operations and its cash flows for the three and six months ended June 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.
Use of Estimates	(b) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates. Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.
Basic and Diluted Net Income (Loss) per Share	(c) Basic and Diluted Net Income (Loss) per Share Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.
Cash and Cash Equivalents	(d) Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.
Issuance Costs Associated with Equity Issuances	(e) Issuance Costs Associated with Equity Issuances Issuance costs incurred in connection with the Company’s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.
Fair Value of Financial Instruments	(f) Fair Value of Financial Instruments The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.
Research and Development	(g) Research and Development Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.
Grant Income	(h) Grant Income Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.
Share-Based Compensation	(i) Share-Based Compensation Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur. Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment. The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.
Income Taxes	(j) Income Taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2021 and December 31, 2020, the Company has recorded a full valuation allowance against its deferred tax assets. The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at June 30, 2021 or December 31, 2020.
Recent Accounting Pronouncements	(k) Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company’s financial statements.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2021

Fair Value Measurements

Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis


			Fair Value Measurement at
			June 30, 2021
	Carrying Value		Level 1		Level 2		Level 3
Cash and cash equivalents	$	49,224,198	$	49,224,198	$	—	$	—


			Fair Value Measurement at
			December 31, 2020
	Carrying Value		Level 1		Level 2		Level 3
Cash and cash equivalents	$	8,074,658	$	8,074,658	$	—	$	—

XML 35 R24.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2021

Prepaid Expenses and Other Current Assets

Schedule of prepaid expenses and other current assets


	June 30,		December 31,
	2021		2020
Prepaid insurance	$	213,892	$	26,542
Prepaid expenses		48,283		11,690
Security deposit		9,865		6,444
	$	272,040	$	44,676

XML 36 R25.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2021

Accrued Expenses

Schedule of accrued expenses


	June 30,		December 31,
	2021		2020
Payroll and related benefits	$	388,437	$	16,493
Accrued professional and clinical fees		353,977		216,198
Accrued license payments		26,833		3,833
	$	769,247	$	236,524

XML 37 R26.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2021

Net Loss Per Share

Schedule of basic and diluted net loss per share


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Numerator:
Net loss	$	(2,524,602)	$	(2,309,490)	$	(5,724,275)	$	(2,751,080)
Denominator:
Weighted-average common shares outstanding, basic and diluted		7,366,654		6,860,847		7,144,870		5,730,158

Net loss per share, basic and diluted	$	(0.34)	$	(0.34)	$	(0.80)	$	(0.48)

Schedule of shares excluded from the computation of diluted weighted-average shares outstanding


	June 30,
	2021	2020
Stock options	961,653	903,847
Warrants	2,400	100,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

Nature of Business and Liquidity (Details) - USD ($)			3 Months Ended		6 Months Ended
Nature of Business and Liquidity (Details) - USD ($)	May 26, 2021	Jan. 31, 2020	Jun. 30, 2021	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Nature of Business and Liquidity
Revenue					$ 0
Accumulated deficit			$ (19,963,350)		(19,963,350)		$ (14,239,075)
Gross proceeds from issuance of common shares					$ 46,673,869	$ 12,034,406
Underwriters warrants
Nature of Business and Liquidity
Number of warrants issued		100,000
Exercise price		$ 7.50
Percentage of exercise price to the share offering price		125.00%
Common Stock
Nature of Business and Liquidity
Issuance of common stock			1,000,000	2,300,000
Number of shares issued for the conversion of redeemable convertible preferred stock				4,117,089
Number of common shares issued upon conversion of notes				118,470
Common Stock \| IPO and Over-Allotment Option
Nature of Business and Liquidity
Issuance of common stock		2,300,000
Share price		$ 6.00
Gross proceeds from issuance of common shares		$ 13,800,000
Net proceeds from issuance of common shares		$ 12,000,000.0
Common Stock \| IPO
Nature of Business and Liquidity
Number of shares issued for the conversion of redeemable convertible preferred stock		4,117,089
Number of common shares issued upon conversion of notes		118,470
Common Stock \| Secondary Public Offering
Nature of Business and Liquidity
Issuance of common stock	1,000,000
Share price	$ 50.00
Gross proceeds from issuance of common shares	$ 50,000,000.0
Net proceeds from issuance of common shares	$ 46,700,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurements
Cash and cash equivalents, Carrying Value	$ 49,224,198	$ 8,074,658
Recurring \| Level 1
Fair Value Measurements
Cash and cash equivalents, Fair Value	$ 49,224,198	$ 8,074,658

XML 40 R29.htm IDEA: XBRL DOCUMENT

Grant Receivable (Details) - USD ($)	3 Months Ended		6 Months Ended
Grant Receivable (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Sep. 30, 2019
Grant Receivable
Grant income	$ 7,414	$ 208,261	$ 36,754	$ 365,699
NIH
Grant Receivable
Notice of Award, grant amount						$ 1,900,000
Grant income	7,414	$ 208,261	36,754	365,699
Proceeds from grants			36,754	$ 901,553
Grant receivable	$ 0		$ 0		$ 0

XML 41 R30.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets
Prepaid insurance	$ 213,892	$ 26,542
Prepaid expenses	48,283	11,690
Security deposit	9,865	6,444
Total prepaid expenses and other current assets	$ 272,040	$ 44,676

XML 42 R31.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accrued Expenses
Payroll and related benefits	$ 388,437	$ 16,493
Accrued professional and clinical fees	353,977	216,198
Accrued license payments	26,833	3,833
Total accrued expenses	$ 769,247	$ 236,524

XML 43 R32.htm IDEA: XBRL DOCUMENT

Convertible Promissory Notes (Details) - USD ($)		1 Months Ended	3 Months Ended	6 Months Ended
Convertible Promissory Notes (Details) - USD ($)	Jan. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Jun. 30, 2021
Common Stock
Convertible Promissory Notes
Number of common shares issued upon conversion of notes			118,470
Common Stock \| IPO
Convertible Promissory Notes
Number of common shares issued upon conversion of notes	118,470
Convertible promissory notes
Convertible Promissory Notes
Aggregate principal amount		$ 530,000
Stated interest rate		8.00%
Effective interest rate		9.80%
Cash payments for interest				$ 0
Percentage of discount to the initial offering price of shares issued in the IPO		20.00%

XML 44 R33.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Leases (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Leases
Rental expense	$ 12,575	$ 10,336	$ 23,190	$ 20,815

XML 45 R34.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - License Agreement (Details)	1 Months Ended	6 Months Ended
	Nov. 30, 2008 USD ($)	Jun. 30, 2021 USD ($) item	Dec. 31, 2020 USD ($)
License Agreements
Accrued license payments		$ 26,833	$ 3,833
License Agreement \| Horizon Therapeutics, PLC
License Agreements
Minimum annual commitment	$ 46,000
Amended License Agreement \| Horizon Therapeutics, PLC
License Agreements
Accrued license payments		$ 26,833	$ 3,833
Number of milestones achieved \| item		0
Period for advance notice of termination		90 days

XML 46 R35.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Employment Agreements (Details)	Jun. 30, 2021 USD ($)
Executive Officers
Employment Agreements
Maximum aggregate severance payments	$ 930,000

XML 47 R36.htm IDEA: XBRL DOCUMENT

Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)		3 Months Ended
	Jan. 31, 2020 Vote item $ / shares shares	Jun. 30, 2021 $ / shares shares	Mar. 31, 2020 shares	Dec. 31, 2020 $ / shares shares
Redeemable Convertible Preferred Stock and Stockholders' Equity
Number of classes of stock designated \| item	2
Number of common and preferred shares authorized	37,000,000
Common stock, par value (dollars per share) \| $ / shares	$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, par value (dollars per share) \| $ / shares	$ 0.0001	$ 0.0001		$ 0.0001
Number of common shares authorized	35,000,000	35,000,000		35,000,000
Number of preferred shares authorized	2,000,000	2,000,000		2,000,000
Number of vote for each share of common stock \| Vote	1
Preferred stock, shares issued		0		0
Preferred stock, shares outstanding		0		0
Series A Redeemable convertible preferred stock
Redeemable Convertible Preferred Stock and Stockholders' Equity
Conversion of redeemable convertible preferred stock to common stock, shares	5,133,159		5,133,159
Series A-1 Redeemable convertible preferred stock
Redeemable Convertible Preferred Stock and Stockholders' Equity
Conversion of redeemable convertible preferred stock to common stock, shares	630,722		630,722
Common Stock
Redeemable Convertible Preferred Stock and Stockholders' Equity
Issuance of common stock		1,000,000	2,300,000
Number of shares issued for the conversion of redeemable convertible preferred stock			4,117,089
Common Stock \| IPO and Over-Allotment Option
Redeemable Convertible Preferred Stock and Stockholders' Equity
Issuance of common stock	2,300,000
Common Stock \| IPO
Redeemable Convertible Preferred Stock and Stockholders' Equity
Number of shares issued for the conversion of redeemable convertible preferred stock	4,117,089

XML 48 R37.htm IDEA: XBRL DOCUMENT

Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) - Underwriters warrants - $ / shares	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Jan. 31, 2020
Warrants
Number of warrants issued			100,000
Exercise price			$ 7.50
Percentage of exercise price to the share offering price			125.00%
Warrant term			5 years
Number of warrants converted in a non-cash transaction	97,600
Warrants outstanding	2,400	100,000

XML 49 R38.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
Share-Based Compensation (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 01, 2021	May 31, 2021	Dec. 31, 2020	Jan. 31, 2020
Share-Based Compensation
Options outstanding	961,653		961,653				1,111,466
Shares available for future grants	1,168,664		1,168,664
Options granted			0
Share-based compensation expense			$ 31,969	$ 1,111,272
Options, vested and exercisable							1,061,466
Stock Options
Share-Based Compensation
Share-based compensation expense	$ 7,992	$ 1,111,272	$ 31,970	$ 1,111,172
Previous Plans
Share-Based Compensation
Options outstanding								352,282
2019 Plan
Share-Based Compensation
Shares authorized					2,000,000	1,000,000

XML 50 R39.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Basic and diluted net loss per share (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator
Net loss	$ (2,524,602)	$ (3,199,673)	$ (2,309,490)	$ (441,590)	$ (5,724,275)	$ (2,751,080)
Denominator
Weighted-average common shares outstanding, basic and diluted	7,366,654		6,860,847		7,144,870	5,730,158
Net loss per share, basic and diluted	$ (0.34)		$ (0.34)		$ (0.80)	$ (0.48)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 51 R40.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Potential shares excluded from calculation (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Stock Options
Net Loss Per Share
Antidilutive securities excluded from computation of earnings per share	961,653	903,847
Warrants
Net Loss Per Share
Antidilutive securities excluded from computation of earnings per share	2,400	100,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($) $ in Millions	6 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Income Taxes
Income tax expense (benefit)	$ 0.0	$ 0.0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 53 R42.htm IDEA: XBRL DOCUMENT

Related-Party Transactions (Details)		1 Months Ended	3 Months Ended
Related-Party Transactions (Details)	Jan. 31, 2020 shares	Mar. 31, 2019 USD ($) item	Mar. 31, 2020 shares
Common Stock
Related-Party Transactions
Number of common shares issued upon conversion of notes \| shares			118,470
Convertible promissory notes
Related-Party Transactions
Aggregate principal amount \| $		$ 530,000
Issuance of convertible promissory notes to related parties \| Convertible promissory notes
Related-Party Transactions
Number of directors who purchased convertible promissory notes issued by the Company \| item		3
Directors \| Issuance of convertible promissory notes to related parties \| Convertible promissory notes
Related-Party Transactions
Aggregate principal amount \| $		$ 305,000
Directors \| Conversion of promissory notes to common stock \| Convertible promissory notes \| Common Stock
Related-Party Transactions
Number of common shares issued upon conversion of notes \| shares	71,429

XML 54 R43.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - Subsequent events	Jul. 07, 2021 $ / shares shares
Subsequent Events
Options granted \| shares	84,200
Exercise price \| $ / shares	$ 102.85
Options, vesting period (in years)	2 years
Options, term (in years)	P10Y

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 93 238 1 false 26 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://annovisbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Balance Sheets Sheet http://annovisbio.com/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Balance Sheets (Parenthetical) Sheet http://annovisbio.com/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Statements of Operations Sheet http://annovisbio.com/role/StatementStatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock Sheet http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock Statements of Changes in Redeemable Convertible Preferred Stock Statements 5 false false R6.htm 00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit) Sheet http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit Statements of Changes in Stockholders' Equity (Deficit) Statements 6 false false R7.htm 00400 - Statement - Statements of Cash Flows Sheet http://annovisbio.com/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Nature of Business and Liquidity Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity Nature of Business and Liquidity Notes 8 false false R9.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10301 - Disclosure - Fair Value Measurements Sheet http://annovisbio.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 10401 - Disclosure - Grant Receivable Sheet http://annovisbio.com/role/DisclosureGrantReceivable Grant Receivable Notes 11 false false R12.htm 10501 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 12 false false R13.htm 10601 - Disclosure - Accrued Expenses Sheet http://annovisbio.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 13 false false R14.htm 10701 - Disclosure - Convertible Promissory Notes Notes http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes Convertible Promissory Notes Notes 14 false false R15.htm 10801 - Disclosure - Commitments and Contingencies Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity Sheet http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity Redeemable Convertible Preferred Stock and Stockholders' Equity Notes 16 false false R17.htm 11001 - Disclosure - Share-Based Compensation Sheet http://annovisbio.com/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 17 false false R18.htm 11101 - Disclosure - Net Loss Per Share Sheet http://annovisbio.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 18 false false R19.htm 11201 - Disclosure - Income Taxes Sheet http://annovisbio.com/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 11301 - Disclosure - Related-Party Transactions Sheet http://annovisbio.com/role/DisclosureRelatedPartyTransactions Related-Party Transactions Notes 20 false false R21.htm 11401 - Disclosure - Subsequent Events Sheet http://annovisbio.com/role/DisclosureSubsequentEvents Subsequent Events Notes 21 false false R22.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 30303 - Disclosure - Fair Value Measurements (Tables) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://annovisbio.com/role/DisclosureFairValueMeasurements 23 false false R24.htm 30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 24 false false R25.htm 30603 - Disclosure - Accrued Expenses (Tables) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://annovisbio.com/role/DisclosureAccruedExpenses 25 false false R26.htm 31103 - Disclosure - Net Loss Per Share (Tables) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://annovisbio.com/role/DisclosureNetLossPerShare 26 false false R27.htm 40101 - Disclosure - Nature of Business and Liquidity (Details) Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails Nature of Business and Liquidity (Details) Details http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity 27 false false R28.htm 40301 - Disclosure - Fair Value Measurements (Details) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://annovisbio.com/role/DisclosureFairValueMeasurementsTables 28 false false R29.htm 40401 - Disclosure - Grant Receivable (Details) Sheet http://annovisbio.com/role/DisclosureGrantReceivableDetails Grant Receivable (Details) Details http://annovisbio.com/role/DisclosureGrantReceivable 29 false false R30.htm 40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 30 false false R31.htm 40601 - Disclosure - Accrued Expenses (Details) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://annovisbio.com/role/DisclosureAccruedExpensesTables 31 false false R32.htm 40701 - Disclosure - Convertible Promissory Notes (Details) Notes http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails Convertible Promissory Notes (Details) Details http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes 32 false false R33.htm 40801 - Disclosure - Commitments and Contingencies - Leases (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails Commitments and Contingencies - Leases (Details) Details 33 false false R34.htm 40802 - Disclosure - Commitments and Contingencies - License Agreement (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails Commitments and Contingencies - License Agreement (Details) Details 34 false false R35.htm 40803 - Disclosure - Commitments and Contingencies - Employment Agreements (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails Commitments and Contingencies - Employment Agreements (Details) Details 35 false false R36.htm 40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details) Sheet http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details) Details 36 false false R37.htm 40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) Sheet http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) Details http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity 37 false false R38.htm 41001 - Disclosure - Share-Based Compensation (Details) Sheet http://annovisbio.com/role/DisclosureShareBasedCompensationDetails Share-Based Compensation (Details) Details http://annovisbio.com/role/DisclosureShareBasedCompensation 38 false false R39.htm 41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails Net Loss Per Share - Basic and diluted net loss per share (Details) Details 39 false false R40.htm 41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails Net Loss Per Share - Potential shares excluded from calculation (Details) Details 40 false false R41.htm 41201 - Disclosure - Income Taxes (Details) Sheet http://annovisbio.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://annovisbio.com/role/DisclosureIncomeTaxes 41 false false R42.htm 41301 - Disclosure - Related-Party Transactions (Details) Sheet http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://annovisbio.com/role/DisclosureRelatedPartyTransactions 42 false false R43.htm 41401 - Disclosure - Subsequent Events (Details) Sheet http://annovisbio.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://annovisbio.com/role/DisclosureSubsequentEvents 43 false false All Reports Book All Reports anvs-20210630x10q.htm anvs-20210630.xsd anvs-20210630_cal.xml anvs-20210630_def.xml anvs-20210630_lab.xml anvs-20210630_pre.xml anvs-20210630xex31d1.htm anvs-20210630xex31d2.htm anvs-20210630xex32d1.htm anvs-20210630xex32d2.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 61 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "anvs-20210630x10q.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 93, "dts": { "calculationLink": { "local": [ "anvs-20210630_cal.xml" ] }, "definitionLink": { "local": [ "anvs-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "anvs-20210630x10q.htm" ] }, "labelLink": { "local": [ "anvs-20210630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "anvs-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "anvs-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 296, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 12, "http://xbrl.sec.gov/dei/2020-01-31": 7, "total": 19 }, "keyCustom": 33, "keyStandard": 205, "memberCustom": 12, "memberStandard": 13, "nsprefix": "anvs", "nsuri": "http://annovisbio.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://annovisbio.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Fair Value Measurements", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:GrantsReceivableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Grant Receivable", "role": "http://annovisbio.com/role/DisclosureGrantReceivable", "shortName": "Grant Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:GrantsReceivableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Accrued Expenses", "role": "http://annovisbio.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Convertible Promissory Notes", "role": "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes", "shortName": "Convertible Promissory Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Commitments and Contingencies", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity", "role": "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity", "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Share-Based Compensation", "role": "http://annovisbio.com/role/DisclosureShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Net Loss Per Share", "role": "http://annovisbio.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Income Taxes", "role": "http://annovisbio.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Balance Sheets", "role": "http://annovisbio.com/role/StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Related-Party Transactions", "role": "http://annovisbio.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Subsequent Events", "role": "http://annovisbio.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Fair Value Measurements (Tables)", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Accrued Expenses (Tables)", "role": "http://annovisbio.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Net Loss Per Share (Tables)", "role": "http://annovisbio.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Nature of Business and Liquidity (Details)", "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "shortName": "Nature of Business and Liquidity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_InitialPublicOfferingAndOverAllotmentOptionMember_o0bfSlyugUeKNISH8-R6gA", "decimals": "2", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_esJpFjknMU-z95uEYv22Gw", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Fair Value Measurements (Details)", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0wGo-42_okqY6IT0u22DCw", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_aQqHSLsB-EuqEI9pRT1nFA", "decimals": "0", "first": true, "lang": null, "name": "anvs:IncomeFromGrants", "reportCount": 1, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Grant Receivable (Details)", "role": "http://annovisbio.com/role/DisclosureGrantReceivableDetails", "shortName": "Grant Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "anvs:GrantsReceivableDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_9_30_2019_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_VGx8ETUxOUmVAteXyafviA", "decimals": "-5", "lang": null, "name": "anvs:GrantsReceivableNoticeOfAwardAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_esJpFjknMU-z95uEYv22Gw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Balance Sheets (Parenthetical)", "role": "http://annovisbio.com/role/StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_12_31_2020_x3i1kT7kaEuP2zRBo2tFqw", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_YVO-Iym2CEyqFfpG7E6ULw", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Accrued Expenses (Details)", "role": "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_celXtefTNE6cYx3IojAelg", "decimals": "INF", "first": true, "lang": null, "name": "anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes", "reportCount": 1, "unitRef": "Unit_Standard_shares_YVO-Iym2CEyqFfpG7E6ULw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Convertible Promissory Notes (Details)", "role": "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "shortName": "Convertible Promissory Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_0nI_4QnTf0usXS2c0_y7Jg", "decimals": "2", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_TA6TytSLjkenQwu6qva5ig", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_aQqHSLsB-EuqEI9pRT1nFA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Commitments and Contingencies - Leases (Details)", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails", "shortName": "Commitments and Contingencies - Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_aQqHSLsB-EuqEI9pRT1nFA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "0", "first": true, "lang": null, "name": "anvs:AccruedLicensePaymentsCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Commitments and Contingencies - License Agreement (Details)", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "shortName": "Commitments and Contingencies - License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_11_1_2008_To_11_30_2008_srt_CounterpartyNameAxis_anvs_HorizonTherapeuticsPlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_EHktSON0jkaJhka4vK3Wgg", "decimals": "0", "lang": null, "name": "anvs:LicenseAgreementMinimumAnnualCommitment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_zqCIxKw6x0irJvjsNuesEA", "decimals": "0", "first": true, "lang": null, "name": "anvs:MaximumAggregateSeverancePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "shortName": "Commitments and Contingencies - Employment Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_zqCIxKw6x0irJvjsNuesEA", "decimals": "0", "first": true, "lang": null, "name": "anvs:MaximumAggregateSeverancePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_1_31_2020_V2Hz-_LtXUqf-vNV7mhwog", "decimals": "INF", "first": true, "lang": null, "name": "anvs:NumberOfClassesOfStockDesignated", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_kpO13K3i-06jID7X98RbFw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)", "role": "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_1_31_2020_V2Hz-_LtXUqf-vNV7mhwog", "decimals": "INF", "first": true, "lang": null, "name": "anvs:NumberOfClassesOfStockDesignated", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_kpO13K3i-06jID7X98RbFw", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_RnweJ-SkEkqQRLk0x8n2_w", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares_YVO-Iym2CEyqFfpG7E6ULw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)", "role": "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails", "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_RnweJ-SkEkqQRLk0x8n2_w", "decimals": null, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_yOxbucq1eUyxAZ2BclzpIQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_YVO-Iym2CEyqFfpG7E6ULw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Share-Based Compensation (Details)", "role": "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails", "shortName": "Share-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_12_31_2020_x3i1kT7kaEuP2zRBo2tFqw", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_YVO-Iym2CEyqFfpG7E6ULw", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_aQqHSLsB-EuqEI9pRT1nFA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)", "role": "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share - Basic and diluted net loss per share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_aQqHSLsB-EuqEI9pRT1nFA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Statements of Operations", "role": "http://annovisbio.com/role/StatementStatementsOfOperations", "shortName": "Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_aQqHSLsB-EuqEI9pRT1nFA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_nczlXfzHWEG5Tv3x4nIF7g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_YVO-Iym2CEyqFfpG7E6ULw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)", "role": "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails", "shortName": "Net Loss Per Share - Potential shares excluded from calculation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_nczlXfzHWEG5Tv3x4nIF7g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_YVO-Iym2CEyqFfpG7E6ULw", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Income Taxes (Details)", "role": "http://annovisbio.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_celXtefTNE6cYx3IojAelg", "decimals": "INF", "first": true, "lang": null, "name": "anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes", "reportCount": 1, "unitRef": "Unit_Standard_shares_YVO-Iym2CEyqFfpG7E6ULw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Related-Party Transactions (Details)", "role": "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_3_1_2019_To_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_mI9pSE-1KEGHdksfIc3dPg", "decimals": "INF", "lang": null, "name": "anvs:RelatedPartyTransactionNumberOfCompanyDirectors", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_kpO13K3i-06jID7X98RbFw", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_7_7_2021_To_7_7_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1fOzM6KY9UyDMuXneogtNQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_YVO-Iym2CEyqFfpG7E6ULw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Subsequent Events (Details)", "role": "http://annovisbio.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_7_7_2021_To_7_7_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1fOzM6KY9UyDMuXneogtNQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_YVO-Iym2CEyqFfpG7E6ULw", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_oT1cyIW7xEanCfmbijd5Cw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock", "role": "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock", "shortName": "Statements of Changes in Redeemable Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_oT1cyIW7xEanCfmbijd5Cw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y5EsyqNPe0KW2CzByjmjZg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit)", "role": "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit", "shortName": "Statements of Changes in Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_celXtefTNE6cYx3IojAelg", "decimals": "0", "lang": null, "name": "anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Statements of Cash Flows", "role": "http://annovisbio.com/role/StatementStatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_POeYHxG8TEqtFucf2Qi45A", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of Business and Liquidity", "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity", "shortName": "Nature of Business and Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_zX6EnWVzgU-oKRds2gkSmQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 26, "tag": { "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accrued Liabilities and Interest, and Employee-Related Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "anvs_AccruedLicensePaymentsCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license payments.", "label": "Accrued License Payments, Current", "terseLabel": "Accrued license payments" } } }, "localname": "AccruedLicensePaymentsCurrent", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "anvs_CommonStockAndPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pertaining to both common stock and preferred stock.", "label": "Common Stock And Preferred Stock [Member]", "terseLabel": "Common Stock And Preferred Stock [Member]" } } }, "localname": "CommonStockAndPreferredStockMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "domainItemType" }, "anvs_CommonStockAndPreferredStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock And Preferred Stock, Shares Authorized", "terseLabel": "Number of common and preferred shares authorized" } } }, "localname": "CommonStockAndPreferredStockSharesAuthorized", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the conversion of convertible promissory notes, including embedded derivative, to common stock", "label": "Conversion of Convertible Promissory Notes, Including Embedded Derivative, to Common Stock", "verboseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock" } } }, "localname": "ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In the conversion of promissory notes to common shares, the percentage discount to the initial offering price of shares issued in the IPO.", "label": "Conversion Of Convertible Securities, Convertible Promissory Notes, Percentage of Discount To Initial Public Offering Price", "terseLabel": "Percentage of discount to the initial offering price of shares issued in the IPO" } } }, "localname": "ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the conversion of redeemable convertible preferred stock to common stock.", "label": "Conversion of Redeemable Convertible Preferred Stock to Common Stock", "verboseLabel": "Conversion of redeemable convertible preferred stock to common stock" } } }, "localname": "ConversionOfRedeemableConvertiblePreferredStockToCommonStock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "anvs_ConversionOfWarrantsNumberOfWarrantsConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants converted in a noncash (or part noncash) transaction.", "label": "Conversion of Warrants, Number of Warrants Converted", "terseLabel": "Number of warrants converted in a non-cash transaction" } } }, "localname": "ConversionOfWarrantsNumberOfWarrantsConverted", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "anvs_CumulativeNumberOfMilestonesAchieved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The cumulative number of milestones achieved.", "label": "Cumulative Number of Milestones Achieved", "terseLabel": "Number of milestones achieved" } } }, "localname": "CumulativeNumberOfMilestonesAchieved", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic and Diluted, Denominator [Abstract]", "terseLabel": "Denominator" } } }, "localname": "EarningsPerShareBasicAndDilutedDenominatorAbstract", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic and Diluted, Numerator [Abstract]", "terseLabel": "Numerator" } } }, "localname": "EarningsPerShareBasicAndDilutedNumeratorAbstract", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "anvs_EquityIncentivePlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Company's 2019 Equity Incentive Plan.", "label": "Equity Incentive Plan2019 [Member]", "terseLabel": "2019 Plan" } } }, "localname": "EquityIncentivePlan2019Member", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "anvs_GrantIncomePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for grant income.", "label": "Grant Income [Policy Text Block]", "terseLabel": "Grant Income" } } }, "localname": "GrantIncomePolicyTextBlock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "anvs_GrantsReceivableDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available", "label": "Grant Receivable" } } }, "localname": "GrantsReceivableDisclosureAbstract", "nsuri": "http://annovisbio.com/20210630", "xbrltype": "stringItemType" }, "anvs_GrantsReceivableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for grants receivables.", "label": "Grants Receivable Disclosure [Text Block]", "terseLabel": "Grant Receivable" } } }, "localname": "GrantsReceivableDisclosureTextBlock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivable" ], "xbrltype": "textBlockItemType" }, "anvs_GrantsReceivableNoticeOfAwardAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of grant awarded.", "label": "Grants Receivable, Notice of Award Amount", "terseLabel": "Notice of Award, grant amount" } } }, "localname": "GrantsReceivableNoticeOfAwardAmount", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "monetaryItemType" }, "anvs_HorizonTherapeuticsPlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Horizon Therapeutics, PLC.", "label": "Horizon Therapeutics Plc [Member]", "terseLabel": "Horizon Therapeutics, PLC" } } }, "localname": "HorizonTherapeuticsPlcMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "anvs_IncomeFromGrants": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.", "label": "Income from Grants", "terseLabel": "Grant income" } } }, "localname": "IncomeFromGrants", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "anvs_IncreaseDecreaseDeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the deferred offering costs included in accounts payable and accrued liabilities.", "label": "Increase (Decrease) Deferred Offering Costs Included in Accounts Payable and Accrued Liabilities", "terseLabel": "Common stock issuance costs in accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseDeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "anvs_IncreaseDecreaseInGrantsReceivable": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in grants receivable.", "label": "Increase (Decrease) in Grants Receivable", "negatedLabel": "Grant receivable" } } }, "localname": "IncreaseDecreaseInGrantsReceivable", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "anvs_InitialPublicOfferingAndOverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public and right given to the underwriter to sell additional shares over the initial allotment.", "label": "Initial Public Offering And Over Allotment Option [Member]", "terseLabel": "IPO and Over-Allotment Option" } } }, "localname": "InitialPublicOfferingAndOverAllotmentOptionMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "domainItemType" }, "anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for issuance costs associated with equity issuances.", "label": "Issuance Costs Associated with Equity Issuances [Policy Text Block]", "terseLabel": "Issuance Costs Associated with Equity Issuances" } } }, "localname": "IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "anvs_LicenseAgreementMinimumAnnualCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount of annual commitment under the terms of a license agreement.", "label": "License Agreement, Minimum Annual Commitment", "terseLabel": "Minimum annual commitment" } } }, "localname": "LicenseAgreementMinimumAnnualCommitment", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of advance notice required to terminate the license agreement.", "label": "License Agreement, Period of Advance Notice of Termination", "terseLabel": "Period for advance notice of termination" } } }, "localname": "LicenseAgreementPeriodOfAdvanceNoticeOfTermination", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "durationItemType" }, "anvs_LicenseAgreementTermsAmendedMay2012Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements, as amended May 2012, under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms Amended May2012 [Member]", "terseLabel": "Amended License Agreement" } } }, "localname": "LicenseAgreementTermsAmendedMay2012Member", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "anvs_LicenseAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "License Agreements" } } }, "localname": "LicenseAgreementsAbstract", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "anvs_MaximumAggregateSeverancePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.", "label": "Maximum Aggregate Severance Payments", "terseLabel": "Maximum aggregate severance payments" } } }, "localname": "MaximumAggregateSeverancePayments", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the National Institute on Aging of the National Institutes of Health.", "label": "National Institute On Aging Of National Institutes Of Health [Member]", "terseLabel": "NIH" } } }, "localname": "NationalInstituteOnAgingOfNationalInstitutesOfHealthMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "domainItemType" }, "anvs_NatureOfBusinessAndLiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Nature of Business and Liquidity [Abstract]", "terseLabel": "Nature of Business and Liquidity" } } }, "localname": "NatureOfBusinessAndLiquidityAbstract", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "stringItemType" }, "anvs_NumberOfClassesOfStockDesignated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of classes of stock designated.", "label": "Number of classes of stock designated", "terseLabel": "Number of classes of stock designated" } } }, "localname": "NumberOfClassesOfStockDesignated", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "integerItemType" }, "anvs_NumberOfVotesForEachShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of vote for each share of common stock.", "label": "Number of Votes for Each Share of Common Stock", "terseLabel": "Number of vote for each share of common stock" } } }, "localname": "NumberOfVotesForEachShareOfCommonStock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "integerItemType" }, "anvs_PercentageOfExercisePriceToShareOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of exercise price to the share offering price.", "label": "Percentage of Exercise Price to the Share Offering Price", "terseLabel": "Percentage of exercise price to the share offering price" } } }, "localname": "PercentageOfExercisePriceToShareOfferingPrice", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "percentItemType" }, "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.", "label": "Prepaid Expense, Security Deposits, and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "anvs_PreviousPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to previous plans.", "label": "Previous Plans [Member]", "terseLabel": "Previous Plans" } } }, "localname": "PreviousPlansMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "anvs_ProceedsFromGrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from grants.", "label": "Proceeds from Grants", "terseLabel": "Proceeds from grants" } } }, "localname": "ProceedsFromGrants", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "monetaryItemType" }, "anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the conversion of promissory notes to common stock as a result of the Company's closing of an initial public offering.", "label": "Related Party Transaction Conversion Of Promissory Notes To Common Stock [Member]", "terseLabel": "Conversion of promissory notes to common stock" } } }, "localname": "RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Convertible promissory notes issued by the Company and purchased by related parties.", "label": "Related Party Transaction Issuance Of Convertible Promissory Notes [Member]", "terseLabel": "Issuance of convertible promissory notes to related parties" } } }, "localname": "RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "anvs_RelatedPartyTransactionNumberOfCompanyDirectors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of Company directors who purchased convertible promissory notes issued by the Company.", "label": "Related Party Transaction, Number Of Company Directors", "terseLabel": "Number of directors who purchased convertible promissory notes issued by the Company" } } }, "localname": "RelatedPartyTransactionNumberOfCompanyDirectors", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "integerItemType" }, "anvs_SecondaryPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secondary sale of stock.", "label": "Secondary Public Offering [Member]", "terseLabel": "Secondary Public Offering" } } }, "localname": "SecondaryPublicOfferingMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "domainItemType" }, "anvs_Series1RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A-1 Redeemable convertible preferred stock.", "label": "Series1 Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series A-1 Redeemable convertible preferred stock" } } }, "localname": "Series1RedeemableConvertiblePreferredStockMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "domainItemType" }, "anvs_SeriesaRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Redeemable convertible preferred stock.", "label": "Seriesa Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series A Redeemable convertible preferred stock" } } }, "localname": "SeriesaRedeemableConvertiblePreferredStockMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "domainItemType" }, "anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible notes.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Notes", "terseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering, shares", "verboseLabel": "Number of common shares issued upon conversion of notes" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleNotes", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible preferred stock.", "label": "Stock Issued During Period, Shares, Conversion Of Convertible Securities, Preferred Stock", "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares", "verboseLabel": "Number of shares issued for the conversion of redeemable convertible preferred stock" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "anvs_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Exercise of warrants, shares", "verboseLabel": "Shares issued upon exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of stock issued during the period upon the conversion of convertible promissory notes.", "label": "Stock Issued During Period, Value, Conversion Of Convertible Securities, Convertible Promissory Notes", "terseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of stock issued during the period upon the conversion of convertible preferred stock.", "label": "Stock Issued During Period, Value, Conversion Of Convertible Securities, Preferred Stock", "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "anvs_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "anvs_TemporaryEquityConversionOfPreferredStockToCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion of redeemable convertible preferred stock to common stock.", "label": "Temporary Equity, Conversion of Preferred Stock to Common Stock", "negatedLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering" } } }, "localname": "TemporaryEquityConversionOfPreferredStockToCommonStock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "monetaryItemType" }, "anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of redeemable convertible preferred stock to common stock, shares.", "label": "Temporary Equity, Shares, Conversion of Preferred Stock to Common Stock", "negatedLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares", "verboseLabel": "Conversion of redeemable convertible preferred stock to common stock, shares" } } }, "localname": "TemporaryEquitySharesConversionOfPreferredStockToCommonStock", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "sharesItemType" }, "anvs_UnderwritersWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Underwriters warrants.", "label": "Underwriters Warrants [Member]", "terseLabel": "Underwriters warrants" } } }, "localname": "UnderwritersWarrantsMember", "nsuri": "http://annovisbio.com/20210630", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r36", "r65" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Executive Officers" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r119", "r241" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r8", "r9", "r26" ], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional and clinical fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r179" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r68", "r69", "r70", "r176", "r177", "r178" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Share based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r45", "r53", "r231" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r42", "r53", "r233" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred financing fees" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net Loss Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r62", "r105", "r108", "r114", "r121", "r204", "r208", "r222", "r265", "r272" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r35", "r62", "r121", "r204", "r208", "r222" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r163", "r174" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "verboseLabel": "Basis of Presentation of Interim Unaudited Financial Statements" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r20", "r55" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, Carrying Value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents, Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r56", "r59" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r49", "r55", "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r49", "r223" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r60", "r62", "r80", "r81", "r82", "r84", "r86", "r92", "r93", "r94", "r121", "r222" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Redeemable Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r147", "r162" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of warrants issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r147", "r162" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Grant Receivable" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r130", "r267", "r275" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r127", "r128", "r129", "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Number of common shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock - $0.0001 par value, 35,000,000 shares authorized, and 6,947,120 and 6,891,608 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible promissory notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes." } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Promissory Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r232", "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r28", "r134", "r232" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Convertible Promissory Notes" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r29", "r66", "r140", "r143", "r144", "r145", "r231", "r232", "r234", "r271" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangements [Abstract]", "terseLabel": "Employment Agreements" } } }, "localname": "DeferredCompensationArrangementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "netLabel": "Net loss per share, basic and diluted", "terseLabel": "Basic and diluted loss per common share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r59", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r87", "r88", "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails", "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r68", "r69", "r70", "r72", "r77", "r79", "r91", "r122", "r139", "r146", "r176", "r177", "r178", "r193", "r194", "r224", "r225", "r226", "r227", "r228", "r229", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r161", "r214", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r213", "r214", "r216", "r217", "r219" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r153", "r154", "r159", "r161", "r214", "r248" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r161", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r59", "r220", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantsReceivableCurrent": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Grants Receivable, Current", "terseLabel": "Grant receivable" } } }, "localname": "GrantsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r40", "r105", "r107", "r110", "r113", "r115", "r264", "r268", "r270", "r277" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r187", "r188", "r191", "r195", "r197", "r199", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r63", "r78", "r79", "r104", "r186", "r196", "r198", "r278" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r39", "r59", "r184", "r185", "r188", "r189", "r190", "r192", "r284" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r52" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r52" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r52" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Changes in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Changes in Redeemable Convertible Preferred Stock" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income (expense), net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r47", "r50", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash payments for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Leases" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r62", "r109", "r121", "r205", "r208", "r209", "r222" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r62", "r121", "r222", "r266", "r274" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r27", "r62", "r121", "r205", "r208", "r209", "r222" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r29", "r132" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r49" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r49", "r51", "r54" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r37", "r38", "r41", "r54", "r62", "r71", "r73", "r74", "r75", "r76", "r78", "r79", "r83", "r105", "r107", "r110", "r113", "r115", "r121", "r222", "r269", "r276" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r105", "r107", "r110", "r113", "r115" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rental expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business and Liquidity" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r212" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business and Liquidity" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r3", "r6", "r124" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r163", "r174" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Number of preferred shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock - $0.0001 par value, 2,000,000 shares authorized, and 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r4", "r6", "r123", "r124" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "verboseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r46" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs", "verboseLabel": "Gross proceeds from issuance of common shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r46", "r175" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r37", "r38", "r48", "r62", "r71", "r78", "r79", "r105", "r107", "r110", "r113", "r115", "r121", "r203", "r206", "r207", "r210", "r211", "r222", "r270" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable convertible preferred stock" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r160", "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r160", "r238", "r239", "r242" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r160", "r238", "r242", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r236", "r237", "r239", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r181", "r285" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r21", "r59", "r125", "r126", "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r146", "r179", "r273", "r282", "r283" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r68", "r69", "r70", "r72", "r77", "r79", "r122", "r176", "r177", "r178", "r193", "r194", "r279", "r281" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r102", "r103", "r106", "r111", "r112", "r116", "r117", "r118", "r149", "r150", "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from issuance of common shares" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of shares excluded from the computation of diluted weighted-average shares outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r151", "r152" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r64", "r240", "r242" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r163", "r174" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r31", "r60", "r92", "r93", "r136", "r137", "r138", "r140", "r141", "r142", "r143", "r144", "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r34" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r52" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense", "verboseLabel": "Share-based compensation expense, including stock issued to consultants and advisors" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Options, vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r169", "r174" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options, vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award", "terseLabel": "Options, term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r162", "r167" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r59", "r163", "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r12", "r13", "r14", "r60", "r62", "r80", "r81", "r82", "r84", "r86", "r92", "r93", "r94", "r121", "r139", "r222" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r32", "r68", "r69", "r70", "r72", "r77", "r79", "r91", "r122", "r139", "r146", "r176", "r177", "r178", "r193", "r194", "r224", "r225", "r226", "r227", "r228", "r229", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r68", "r69", "r70", "r91", "r251" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r139", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in initial public offering, net of issuance costs (in shares)", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r139", "r146", "r171" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "verboseLabel": "Exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r139", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in initial public offering, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r32", "r139", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r62", "r120", "r121", "r222" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r61", "r146", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Redeemable Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r230", "r246" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent events" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r230", "r246" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r230", "r246" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r230", "r246" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r245", "r247" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental disclosure of non-cash financing activities:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r53" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedLabel": "Change in fair value of derivative liability", "terseLabel": "Change in fair value of derivative liability" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r95", "r96", "r97", "r98", "r99", "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average number of common shares outstanding, basic and diluted", "verboseLabel": "Weighted-average common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r286": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r287": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r288": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r289": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r291": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r292": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" } }, "version": "2.1" } ZIP 62 0001558370-21-009460-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-21-009460-xbrl.zip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end